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Abstract 
Economic evaluation of health technology using cost-utility analysis (CUA) 
normally applies an extra-welfarist framework in which health, the unit of 
effectiveness, is maximised. Typically, health status is measured by health-
related quality of life (HRQoL) questionnaires to define health states. 
Preferences for health states are valued on a utility scale and combined with the 
time spent in the state to calculate quality-adjusted life years (QALYs). 
This thesis develops methods for measuring and valuing health using the case of 
age-related macular degeneration (AMD), where there are limitations with 
current methods for calculating QALYs. 
How do widely used methods for deriving health state utility values in AMD 
perform and how can these methods be improved? 
In order to estimate utility, preferences for health states must be elicited. This is 
generally conducted from a personal ex ante perspective, in a representative 
sample of the public. However, limitations with the descriptive aspects of 
HRQoL questionnaires mean that the public valuers may lack information to 
express informed preferences. 
This thesis investigates the performance of questionnaires and addresses the 
impact of informing the public when valuing health states. 
Are non-health attributes important in AMD and how can they be incorporated 
into the cost-utility economic evaluation framework? 
The objective of maximising health can be at odds with some of the broader 
aims of health care systems such as promoting equity or improving the process 
of care. 
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This thesis develops weightings for health state utilities that represent a 
broader utility function incorporating preferences for non-health attributes and 
investigates the impact of perspective when valuing these attributes. It also 
develops a conceptual framework for assessing the economic value of decision 
aids. 
How is visual function associated with utility in AMD and how can the association 
be applied to economic evaluation? 
For economic evaluation, the long-term impact of a treatment generally 
requires health states from clinical trials to be extended using modelling 
techniques. In AMD, health states are normally defined by levels of visual acuity 
(VA). 
This thesis finds that the association between VA and utility is weak, 
demonstrates impact of an alternative visual function measure on CUA and 
develops a mapping algorithm from visual function to utility. 
What is the economic impact of treating AMD patients with good starting vision? 
Initiating treatment in patients with early AMD is shown to be cost-effective 
compared with current practice using an economic model based on real world 
outcomes.  
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1. Introduction 
This chapter introduces the background to economic evaluation. Specific 
emphasis is placed on the calculation of quality-adjusted life years (QALYs) for 
use in cost-utility analysis (CUA) including the stages in health state 
measurement and valuation required to calculate QALYs. The chapter also 
describes age-related macular degeneration (AMD) as a disease and the current 
treatment option available to patients with AMD. 
 
1.1. Economic evaluation of health technology 
1.1.1. Cost-utility analysis 
In order to determine whether to fund a healthcare programme, health systems 
require a methodology for comparing the relative value for money of 
interventions. Within the budget constraint of a single-payer system such as the 
UK (United Kingdom) National Health Service (NHS), the payer must decide 
which services offer the greatest benefit relative to cost. This often involves 
making choices between funding interventions for different conditions that 
generate outcomes that are not directly comparable. For example, a drug for 
cancer patients, which reduces pain and extends life or cataract surgery, which 
improves vision. 
Health care decision makers within the NHS are increasingly employing CUA. 
The CUA approach aims to maximise health outcomes thereby takes an extra-
welfarist approach to economic evaluation. It may be considered a specific form 
of cost-effectiveness analysis (CEA) where the measure of effectiveness 
 20 
incorporates preferences for health. Outcomes are generic and incorporate the 
notion of value so facilitate comparisons across healthcare programmes. The 
QALY, which combines the quality and length of life into a single unit, is the 
most commonly used unit of health outcome.(1) 
The National Institute for Health and Care Excellence (NICE) has published 
guidelines on health technology assessment (HTA) in which it recommends CUA 
for the economic evaluation of new interventions. It recommends that QALYs 
should be calculated from health state utility values derived from a generic 
preference based health-related quality of life (HRQoL) questionnaire that has 
been valued in the UK general population.(2) Such an approach allows 
outcomes across conditions to be compared on a common scale reflecting 
societal preferences. 
1.1.2. Quality-adjusted life years 
QALYs combine the value of quality of life and length of life into a single score 
that may be used in CUA. The demand to use a scale that is comparable across 
diseases is driven by policymakers who wish to allocate resources according to 
the wishes of stakeholders within a resource-constrained health care system.(1) 
To calculate a QALY, a quality weight is applied to the duration of time spent in a 
health state: QALY= duration*quality of life weight. For example, one year spent 
in perfect health (or full health) would accrue 1 QALY (1*1=1). 
Figure 1.1 illustrates this using a simple example.  In the example, remaining 
length of survival is 5 years, at a decreasing level of quality of life. In the first 
year quality of life is valued at 0.7 (i.e. 70% of perfect health), 0.6 in years 2 and 
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3, and 0.4 in the final two years of life. The total QALYs in this case would be 2.7 
QALYs [(0.7*1) + (0.6*2) + (0.4*2)= 2.7 QALYs.] The quality of life ‘weights’ used 
in the calculation of QALYs are utility values described in Section 1. 
 
 
Figure 1.1. Plot of a QALY. 
1.1.3. Utility 
The quality component of the QALY requires that preferences for health states 
are measured on a utility scale anchored by perfect health at 1 and death at 
0.(3) This calculation is particularly important for vision disorders, which have 
a major impact on quality of life, but, in general, a more minor impact on length 
of life.  
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Utility values used in CUA are based on von Nuemann-Morgenstern (vN-M) 
utility theory: a representation of how a rational individual should behave. 
According to vN-M utility theory, scores represent the strength of an 
individual’s preference, under uncertainty, for a described health state.  
There are a number of conditions that utilities should meet, and although the 
definition of health state utility is a normative one, it should somewhat reflect 
the way individuals make decisions when faced with uncertainty (although 
empirical evidence has suggested that these conditions may be more often 
violated than met).(4, 5) 
vN-M utility theory also assumes that utility scores are cardinal in that 
individuals are able to quantify the extent to which they prefer one health state 
to another. This is as opposed to scores being ordinal, individuals are only able 
to order health states in terms of preference. Theoretically, utility scores that 
form the basis of QALYs are meant to have these qualities, making them as close 
as possible to the utility scores in vN-M utility theory. The term “utility” in vN-M 
utility theory and in the calculation of QALYs therefore has a different definition 
and use to the term utility in welfare economic theory and Pareto 
optimisation.(4) 
The source of these utilities requires a decision on who is best placed to value 
health states and whose preferences should count.(6) HTA bodies such as NICE 
in England and Wales recommend that public preferences be used in the 
economic evaluation of health technologies.(2) As payers in a tax-funded health 
system, it is considered right that the public’s preferences are taken into 
account when allocating health care resources. Furthermore, the public offers 
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an unbiased view of health states, unaffected by the condition they are 
valuing.(7) They express their preferences from behind a “veil of ignorance”. 
Consequently the Washington Panel on Cost Effectiveness in Health and 
Medicine recommended that “weights for QALYs should be based on community 
preferences rather than those of patients, providers or investigators”.(8) 
The standard technique for public preferences to be taken into account is for 
patients to answer a HRQoL questionnaire to classify their health state into a 
profile. A sample of the general public generates a value anchored by 0 as dead 
and 1 as perfect health for each health state profile. These data are used to 
create a tariff for converting patient scores onto a scale of health state utility 
values. 
Critics of this procedure point out that members of the public are unlikely to 
have all of the information required to provide informed preferences for life in a 
health state. 
 
1.1.4. Alternatives to the QALY 
There are various alternatives to the use of QALYs to capture the value of health 
impacts. Monetary measures are commonly used in economic evaluations and 
methods are described in the Treasury Green Book.(9) Although less common 
than QALYs for valuing health interventions in the UK, monetary measures have 
been used in health economic evaluations. In addition QALYs may be converted 
to monetary values for the purpose of calculating the net benefit of an 
intervention. Typically the value of £20,000 per additional QALY gained is used 
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as the value reflecting the lower bound of the NICE cost-effectiveness threshold; 
however higher thresholds of £30,000 and £50,000 may be used depending on 
the nature of the condition and intervention.(2) 
The healthy year equivalent (HYE) metric was originally proposed in the late 
1960s.(10) One of the key differences between HYEs and QALYs is that the HYE 
values a profile of health over time, whereas in the QALY each health state is 
valued independently and then summed to form a profile. The advantage of the 
HYE is therefore that it is able to capture different values for ill health 
depending on when they occur in the overall profile of health; however, partly 
owing to complexities of valuation and calculation, HYEs are not routinely used 
for the evaluation of health interventions. 
Disability adjusted life years (DALYs) are also used to capture the health of 
populations and is the preferred measure of the World Health Organisation 
(WHO).(11) DALYs are calculated as the sum of the Years of Life Lost (YLL) due 
to premature mortality in the population with the condition of interest and the 
sum of the Years Lost due to Disability (YLD) for people living with the 
condition. The quality weight, YLD, is calculated as the number of incident cases 
multiplied by a disability weight and the average duration. Amendments were 
made to the methodology of DALY weighting in 2010.(12)  The updated 
disability weights were based on data from household surveys conducted in five 
countries (Bangladesh, Indonesia, Peru, the United Republic of Tanzania and the 
United States of America) and a web-based survey. DALYs currently remain, 
however, more frequently used in evaluations of health in developing countries 
and for comparing population health internationally, than for economic 
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evaluations of health interventions in single-payer health care systems such as 
the UK. 
The European Commission (EC) has developed an indicator referred to as 
Healthy Life Years (HLY). These reflect the number of years a person can expect 
to live without disability, adjusted for their age. There are two components to 
the HLY: mortality which is assessed through national life tables and data on 
activity limitation. The data on activity limitation are obtained from the General 
Activity Limitation Indicator  (GALI) included within an EU survey 
(Eurostat);(13) however as this measure is not preference-based it does not 
reflect ‘value’ as usually required for economic evaluations. 
1.2. Measurement of health benefits 
1.2.1. Health state classification systems 
The general approach to measuring health states for CUA is to obtain patient 
reported description of health status across relevant dimensions using a 
validated HRQoL instrument. 
NICE recommends the EQ-5D for measuring and valuing health states for CUA. 
However, there is evidence that generic health-related quality of life 
questionnaires such as the EQ-5D with just 5 questions and, until recently, 3 
levels are not sufficiently sensitive to capture changes in health status in vision 
and other diseases that primarily affect function.(14) Condition-specific 
measures may be more sensitive, but suffer from a lack of comparability across 
diseases. The lack of comparability can even apply to condition-specific 
preference scales used in CUA.(15) 
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1.2.2. Generic HRQoL 
Generic preference-based HRQoL questionnaires are a frequently used method 
for estimating health state utilities for economic evaluation. These 
questionnaires consist of a descriptive system that cover HRQoL and is 
therefore relevant to all health conditions. 
Measures tend to focus on how does one’s health impact on how one feels and 
how well one is able to do the things in life that make a life go better or worse. 
Questionnaires use a number of general domains that measure health across all 
conditions. Scores on these domains must then be aggregated to provide an 
overall health-state classification.   
Which set of domains is to be used in measuring HRQoL remains an area of 
research and can have considerable impact on the results obtained. A 
comparison of the EQ-5D and SF-6D across different patient groups found 
significant differences in agreement across the groups and across severity 
levels.(16) 
The reasons for selecting one health state classification system over another can 
range from philosophical concerns about what ought to matter when evaluating 
health, to psychometric issues concerning how responses to items on domains 
should or should not be correlated. To provide an idea of what the different 
health state classification systems focus on in terms of what is important in 
HRQoL, below are the domains used by the three most prominent systems 
currently used for generating utilities for health economic evaluation: the EQ-
5D, the SF-6D, and the Health Utilities Index 3 (HUI-3): 
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• EQ-5D: anxiety/depression; pain/discomfort; usual activities; self-care; 
mobility. 
• SF-6D: physical functioning; role limitations; social functioning; pain; 
mental health; vitality. 
• HUI-3: vision; hearing; speech; ambulation; dexterity; emotion; 
cognition; pain. 
Preferences for different health states described by responses to the 
questionnaire have been valued separately. For example, the EQ-5D UK value 
set was derived from a sample of UK general public. When a patient responds to 
a questionnaire, it is possible to assign a preference value to their health state 
using this valuation tariff. This procedure is described in Section 1.3. 
 
1.2.2.1. EQ-5D 
The EQ-5D is a generic instrument for the measurement and valuation of health 
status.(17) It was developed by the EuroQoL Group; a multi-national and multi-
disciplinary group of researchers. Although originally developed and tested for 
use in Europe, its use has expanded internationally and there are currently 141 
official language versions of the three-level version of the instrument.  
The EQ-5D consists of a descriptive system and a visual analogue scale (VAS). 
Respondents are requested to complete both parts of the questionnaire with 
regard to their own health ‘today’. The descriptive system includes five 
dimensions of health: mobility; self-care; ability to carry out usual activities; 
pain and discomfort; and anxiety and depression.  In the EQ-5D-3L, each 
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dimension is described in terms of three levels of severity, although a five level 
version has been recently developed and is now increasingly used. The three-
level version describes 243 unique health states, and the five-level version 
describes 3125 possible health states. 
Value sets have been developed by the EuroQol Group to enable each health 
state described by the EQ-5D to be assigned a utility value. The original EQ value 
set was developed for the general population of England, funded by the 
Department of Health.(18) These were obtained from a representative sample 
of 3395 members of the English general population through face-to-face 
interviews.(19) These people were asked to consider a selection of health states 
described by the EQ-5D and then to value them using the time-trade off method. 
A value set for the EQ-5D-5L version for England is expected to be published 
soon and an interim method for deriving utilities via a cross-walk has been 
published for use in the meantime. Value sets are currently available for 13 
other countries for the EQ-5D-3L.(20) 
The EQ-5D has been validated in many different conditions and settings, and is 
the commonly used measure of health outcomes in economic evaluations of 
health technologies.(21)  In the UK, it is recommended by NICE as the preferred 
instrument for measuring health status for QALY calculations.(2) It has also 
been used in large general population surveys including Health Survey for 
England and Understanding Society.(22, 23) The EQ-5D has also been adopted 
by the Department of Health as part of its Patient-Reported Outcome Measures 
(PROMS) programme to routinely measure changes in the health of all patients 
undergoing selected health interventions.(24) 
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Utility scores derived from the EQ-5D have a number of distribution issues. In 
addition to having the qualities of a maximum value of 1 and minimum value of -
0.594, EQ-5D utility scores tend to be positively skewed with an identifiable 
ceiling effect, meaning that EQ-5D data sets often have a large number of 
respondents reporting full health with an EQ-5D value of 1.(16) 
 
1.2.3. Condition-specific HRQoL 
While vision-specific questionnaires such as the NEI VFQ-25 may be developed 
with a more substantial descriptive system,(25) they often do not capture 
comorbidities and side effects of new treatments, and hence are not directly 
comparable to generic HRQoL measures when used to estimate QALYs.(15) 
There has been research into the use of condition specific questionnaires to 
generate health state utilities. In vision, the VisQol was developed as a 
preference-based scale for a vision-specific HRQoL questionnaire.(26, 27) 
Utilities to calculate QALYs require that health states are measured on a 
preference scale bounded by death at 0 and perfect health at 1. The construct of 
HRQoL is used to describe health states. 
It remains to be established whether preferences for condition-specific health 
states, which may not mention other dimensions of health that are not relevant 
to the condition, are equivalent to preferences for generic HRQoL states.(28) 
Furthermore, the interaction of dimensions of HRQoL mean that preference 
scales tend to be non-linear, so a movement on a condition-specific utility scale 
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can be expected to be different from the change on a generic HRQoL utility 
scale.(29, 30) 
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PROM Example instrument 
Vision-specific functioning MAI (Massof Activity Inventory) 
Condition-specific QoL MacDQoL 
Vision-specific QoL NEI-VFQ 25 
Generic HRQoL EQ-5D 
Table 1.1. Hierarchy of PROMs. 
*Adapted from Fenwick et al. (31)  
 
PROMs can be viewed in a hierarchy of specificity to generalizability (Table 
1.1). A model linking physiological variables, symptom states, functional health, 
general health perceptions and overall quality of life in a hierarchical pathway 
suggests that items further along the pathway will correlate more closely with 
quality of life (Figure 2.2).(32) Consequently it can be hypothesized that 
PROMs will correlate more closely with the quality of life of AMD patients than 
visual function measures. 
 
Figure 2.2. Wilson and Cleary's quality of life scheme. 
 
Choosing between generic and condition-specific PROMs is a trade-off. 
Condition-specific measures can be more relevant and sensitive to things that 
Physiological 
variables
Symptom 
states
Functional 
health
General 
health 
perception
Overal quality 
of life
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matter to a patient with the condition. However, they can suffer from 
disadvantages of excluding side effects of treatment, distortions created by 
focusing effects and the potential loss of comparability from preference 
interactions with dimensions not covered by the specific measure.(33) 
1.2.4. Mapping 
Mapping scores from a non-preference-based questionnaire to a preference-
based questionnaire expands the evidence on cost effectiveness by allowing the 
retrospective incorporation of trials that did not include an outcome measure 
suitable for calculating QALYs, therefore increasing the volume of cost 
effectiveness evidence available.(34) 
Dakin identified 121 mapping algorithms from 80 instruments to the EQ-5D in a 
systematic review published in 2013. (35)  A database of these mapping 
algorithms is maintained by researchers at the University of Oxford. 
In order to create a mapping algorithm, the two questionnaires must be 
administered in the same sample of patients and a statistical model fitted to the 
scores. 
Ordinary least squares (OLS), Tobit and censored least absolute deviation 
(CLAD) models, two-part models (TPMs), and latent class models (LCMs) have 
been applied. A review of mapping studies found considerable variability in 
performance of mapping functions in terms of model fit and predictive 
ability.(33) Ideally the datasets used to derive the algorithm and the datasets 
where the model is subsequently applied should be similar in terms of socio-
demographic characteristics and severity of the condition. Furthermore, the 
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performance of the algorithm will be less than or equal to the performance of 
the least sensitive instrument in the mapping (normally the target preference-
based questionnaire).(33) 
 
1.3. Valuation of health benefits 
1.3.1. Direct utility elicitation 
Direct elicitation of utilities involves asking people to consider their own health 
status, usually at the time of asking, and for them to value their health status 
using one of a range of valuation techniques. Currently the most common 
methods used to value health status are VAS, the time trade-off (TTO) method 
and the standard gamble (SG) method. 
The VAS method is arguably the simplest of the measurement techniques. 
Respondents are presented with a vertical or horizontal scale, and requested to 
indicate how they value their health state on that scale.  VAS can differ in terms 
of the presentation of the scale, the numerical values attached to the scale, the 
definitions of the ‘anchors’ or limits at the top and bottom of the scale,  and the 
wording of the question posed to respondents, including the recall period over 
which the respondent should consider their health. In order to be used in QALY 
calculations, respondents must also value a state of ‘dead’ on the VAS in order to 
be converted to the QALY scale on which 0 represents ‘dead’.  Even then, VAS 
scores are a measurable value function representing the strength of preferences 
under certainty so do not meet the conditions of von Neumann-Morgenstern 
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utilities. In contrast, a utility function, such as that measured by the SG or TTO 
technique, represents the strength of preferences under uncertainty. (36) 
One commonly used example of a VAS is the EQ-VAS which is part of the EQ-5D 
questionnaire. This is a 20cm vertical 0 to 100 scale, presented in the form of a 
thermometer.  The anchor at the top of the scale represents the ‘best imaginable’ 
health states (value = 100) and the anchor at the bottom of the scale represents 
‘worst imaginable’ health (value = 0). Respondents are asked to mark on the 
scale the value that best indicates their ‘current health today’ on the scale. The 
standard version of the EQ-VAS does not include a question requesting the 
valuation of the state ‘dead’ and therefore, it is argued, cannot be used to 
estimate utilities for the calculation of QALYs; however valuation surveys may 
include additional questions to anchor on the QALY scale.  
The SG method of valuation incorporates elements of valuation under 
uncertainty and trade-offs between uncertain states of health. Respondents are 
asked to consider spending a specified amount of time, t, in their current health 
state. They are then asked to make a hypothetical choice of remaining in that 
health state or accepting a risky treatment, which could lead to either perfect 
health or immediate death. The utility or value attached to their health state is 
then obtained by varying the chance or probability of the perfect health and 
death until the respondent considers the risky option to be equivalent to the 
certain option of their current health state. Essentially this approach is asking 
people their maximum risk of death that they would be prepared to accept in 
return for the chance of a cure for their condition. 
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The TTO method has been frequently used in health state valuation as it 
embodies the notion of sacrifice between quality of life and length of life, and 
therefore intuitively reflects the trade-off encapsulated in the QALY. 
Respondents are asked to choose between two certain options: (i) a specified 
time period (e.g. remaining life expectancy) in their current health state and (ii) 
a shorter period of time in ‘full’ health. The time spent in perfect health is then 
varied until the respondent thinks both options are similarly desirable and a 
utility is calculated anchored by death (0) and perfect health (1). 
The TTO method was developed specifically for use in health care and has been 
validated against the SG for states better than death.(36). However, a review of 
the TTO literature concluded that the methodology is far from 
standardised.(37) 
There are advantages and disadvantages associated with all three methods. The 
method of elicitation has also been shown to impact on the utilities derived, 
with the VAS tending to generate lower values than the SG.(38) 
The VAS method is arguably the simplest to conduct and can be self-completed 
using online or postal surveys quickly and inexpensively. However it has been 
criticised by economists for a lack of theoretical foundation for eliciting 
preferences due to a lack of explicit trade-off.(39) The standard gamble and TTO 
methods are more commonly used by economists; however these are more 
difficult for respondents to complete, and in particular methods are being 
developed to make the TTO more amenable to valuing states worse than death 
and address issues of time-preference.(40, 41) 
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1.3.2. Discrete choice experiment 
While the TTO is the most widely used valuation technique for eliciting health 
state utility values,(38) it may not provide consistent preferences in AMD 
patients.(42) Ordinal methods such as rank or discrete choice experiment (DCE) 
avoid the key concerns of the TTO in AMD – namely an unwillingness to trade 
any years for an improvement in vision and the cognitive challenges of the 
question in elderly patients. Furthermore, the DCE method is well grounded in 
utility theory.(43) Respondents are required to simultaneously consider several 
attributes of the good being valued therefore the method can be considered a 
specific form of conjoint analysis. 
DCEs are particularly attractive as a method for eliciting preferences for non-
market goods such as the environment and healthcare where it is not possible 
to observe revealed preferences.(44) The original interest in DCEs in health 
economics was due to their flexibility to include non-health benefits such as 
utility derived from the process of care, reassurance or anxiety (compared with 
the SG and TTO which were specifically designed to capture health outcome 
benefits only). In healthcare, DCEs have been used to value patient experience 
such as waiting time, quality of care and health outcomes.(45) The flexibility of 
the valuation task to not be valued against perfect health and death (like the 
TTO and SG) may draw more reliable preferences since aspects of vision may be 
considered to fall outside of health and may include the process in which care is 
delivered.(46) 
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1.3.3. Choice of preferences 
Patients can express preferences for their own health state via the direct 
elicitation methods described above. Patients may represent suitable 
candidates for valuing their health due to their knowledge of the condition, 
removing the need to elicit a health state and conduct a valuation in the public 
who may only be able to process limited information about the state.(6) 
However, living with the condition means that patients cannot express ex ante 
preferences from behind a veil of ignorance.(47) Consequently their 
preferences are not expected utilities that conform to vN-M utility theory due to 
the absence of uncertainty.  
Despite this limitation, patient-elicited utilities have, to date, been used widely 
in the CUA of treatments for eye disease.(48, 49) It can be argued that this has 
been in response to the perceived lack of suitability of questionnaire-derived 
utilities. 
 
1.4. Vision and AMD 
1.4.1. Disease 
Age-related macular degeneration (AMD) is the leading cause of severe visual 
loss in patients over the age of 50 years in Europe and North America.(50, 51) 
Late-stage AMD is the third largest cause of blindness.(52) In the UK, there are 
estimated to be 513,000 cases of AMD and this number is predicted to increase 
to 679,000 cases by 2020.(53)AMD is the leading cause of visual impairment in 
industrialised countries.(52) 
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Neovascular AMD (nAMD) is characterised by choroidal neovascularisation 
(CNV), which is the growth of abnormal, choroidal blood vessels beneath the 
macula, which causes severe loss of vision and is responsible for the majority of 
visual loss due to AMD.(54) 
Patients may find it harder to read, recognise faces, or make out fine detail, 
which can have a severe impact on their quality of life.(55) It predominantly 
affects central vision, having a severe impact on tasks such as reading. 
There are two forms of AMD with distinct causes. nAMD (wet AMD) is caused by 
the development of new blood vessels in the macular. Geographic atrophy, or 
dry AMD, is caused by damage to the macula and a build-up of drusens. It is the 
most common and least serious type of AMD accounting for around 9 out of 10 
cases. 
The loss of vision is gradual, occurring over many years. An estimated 1 in 10 
people with dry AMD will then go on to develop wet AMD.(56) 
 
1.4.2. Impact on HRQoL 
Vision loss has a wide-ranging and often severe impact on patients’ quality of 
life and functioning.(52) As a disease that rarely causes mortality, economic 
evaluations are sensitive to the quality component of the QALY.(57) 
However, it has been suggested that both measurement of changes in HRQoL in 
vision and the valuation of low vision health states fail to fully capture the 
changes in quality of life for economic evaluation. 
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Chronic diseases that limit activities of daily living such as AMD present a 
challenge for eliciting health states as patients often adapt to limitations that 
would initially seem disabling to the general population. 
In AMD, no single visual function outcome captures HRQoL and interventions 
may have a differential impact on each outcome. Visual acuity (VA) and contrast 
sensitivity (CS) both have an impact on quality of life in AMD patients.(58) 
VA measures the eye’s ability to resolve fine detail and is widely used as a proxy 
for health-related quality of life. A number of studies have associated utilities 
with VA. Most notably Brown et al. asked the time trade off question in a sample 
of AMD patients in the US.(48) This has enabled the calculation of QALYs from 
VA outcomes and subsequently this has been used in the majority of economic 
models for treatments of macular degeneration.(49)  
CS measures ability to see low contrast patterns and has also been shown to 
impact on quality of life. Indeed, it may be more appropriate to base economic 
models on CS or some combination of CS and VA rather than on VA alone.(58) 
CS has been associated with utilities via the time trade off, SF-6D, HUI-3 and EQ-
5D.(59) It has been used in one economic model for treatment of macular 
degeneration.(60) 
 
1.4.3. Treatments 
One of the key mediators implicated in the pathogenesis of nAMD is vascular 
endothelial growth factor-A (VEGF). Treatments for CNV target VEGF are 
administered by injection into the vitreous cavity with high binding specificity 
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to VEGF (anti-VEGF agents). These agents are administered by intraocular 
(intravitreal) injections with repeat injections as necessary depending on the 
agent.  
Spending on the anti-VEGF ranibizumab (Lucentis®, Novartis AG, Switzerland) 
accounted for £129mn of the NHS prescribing budget in 2010, making it the 
third most costly drug.(61)  
Economic evaluations of treatments for AMD have concluded that the two anti-
VEGF therapies used within the NHS, approved ranibizumab and off-label 
bevacizumab (Avastin®, Roche Holdings AG, Switzerland), are cost-effective at 
commonly applied thresholds.(2, 62) A recent head-to-head comparison found 
no significant difference between the two drugs in terms of effectiveness.(63) 
There is currently no approved treatment for dry AMD. Patients are provided 
with vision aids such as magnifiers and encouraged to develop strategies to 
adapt to their reduced vision and to maximise the use of their remaining 
vision.(64) 
 
1.5. Concluding remarks 
In conclusion, there is a need to measure changes in HRQoL in order to perform 
CUA of treatments for AMD.  From a methodological point of view, patients 
should report their own health states while the public should value these health 
states in order to reflect society’s preferences.(3) While there remain a variety 
of methods employed, there is an increasing trend for generic HRQoL 
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questionnaires with associated value sets representative of the general public to 
be employed.(65) 
Research aims 
Four related research questions have been identified with the objective of 
developing an improved method for measuring and valuing health benefits in 
vision disorders: 
1. How do widely used methods for deriving health state utility values in 
AMD perform and how can these methods be improved? 
2. Are non-health attributes important in AMD and how can they be 
incorporated into the cost-utility economic evaluation framework? 
3. How is visual function associated with utility in AMD and how can the 
association be applied to economic evaluation? 
4. What is the economic impact of treating AMD patients with good 
starting vision?  
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2. Literature review 
This chapter is a systematic review of the methods to estimate health state 
utility values to calculate QALYs in AMD. The review identifies where 
limitations exist and is used to define the research aims of the subsequent 
chapters of this thesis. 
 
2.1. Introduction 
A literature review was conducted to identify the methods that have been used 
to value health benefits in order to assess the cost effectiveness of treatments 
for AMD following the methodological guidance published by York Centre for 
Review and Dissemination (CRD).(66) It was decided that, due to the focus of 
this thesis on health benefits and the relevance of the QALY within the UK 
healthcare system, the search would be limited to studies that are suitable for 
estimating QALYs. 
A preliminary screen of systematic reviews using the Cochrane Library (which 
includes Cochrane Database of Systematic Reviews (CDSR), the Database of 
Abstracts of Reviews of Effectiveness (DARE) and the HTA Database) identified 
no directly relevant reviews. The closest match was a review titled “Measuring 
quality of life for patients with age-related macular degeneration”.(67) However, 
this did not directly consider measures of economic benefit such as QALYs and 
was conducted a number of years ago (September 2006). 
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2.2. Search question 
The search question was: “How have utility values been estimated for health 
states associated with AMD in order to calculate QALYs?” 
Table 2.2 describes the search question using the system of Population, 
Intervention, Comparison, Outcome (PICO) components.  
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PICO Terms 
Population Macular degeneration and similar retinal diseases 
Intervention Any/all 
Comparison Any/all 
Outcome Health state utilities/QALYs 
Table 2.2. PICO components for search question. 
 
It was determined that health state utilities from other retinal diseases with a 
similar impact on quality of life may be applied to AMD health states, so terms 
to capture these were included in the search strategy. These were conditions 
that also cause central vision loss (retinal vein occlusion, diabetic retinopathy 
and macular oedema). 
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2.3. Search strategy 
 
Term Synonyms 
Macular degeneration and similar retinal 
disease 
“Macular degeneration” 
“Macular disease” 
“Retinal disease” 
 “Macular $edema” 
“Retinal vein occlusion” 
"Diabetic retinopathy" 
Health state utilities/QALYs “Quality$adjusted life year*” 
“QALY*” 
 “EQ$5D” 
 “Euroqol” 
“SF$6D” 
 “HUI” 
“Health utilities index” 
Table 2.3. Search terms 
 
It was decided that to increase the search results, all searches would be done 
with text searches rather than MESH terms in MEDLINE (macular degeneration 
and quality-adjusted life year are MESH terms). All terms were searched as 
multipurpose terms in OVID (.mp: Title, Original Title, Abstract, Subject Heading, 
Name of Substance, and Registry Word fields). The search terms are detailed in 
Table 2.3. 
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Key words EQ-5D, SF-6D and HUI-3 were added to the QALY search in order to 
be sure to capture any papers that used these widely used preference-based 
quality of life questionnaires that are suitable for calculating QALYs. Wildcards 
were employed to account for UK/US spelling (e.g. oedema and edema), 
spaces/hyphens (e.g. EQ-5D and EQ5D) and truncations. 
The search was limited to articles between 1st January 1990 and 31st December 
2012 and to English language abstracts only. The 1990 limit can be justified by 
the fact that the majority of CUA has been conducted in the past 25 years, with 
methodological standards improving over time.(68) 
MEDLINE, EMBASE and PsycINFO databases were searched via the OVID portal. 
HTA and NHS EED databases were searched via the York CRD portal. 
 
2.4. Data extraction 
A data extraction form was piloted then employed as shown in Table 2.4. 
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 Data item 
1. Endnote ID 
2.  Authors 
3.  Title 
4.  Year 
5.  Full reference 
6.  Disease 
7.  Type of paper: Prospective or retrospective trial, economic model, utility 
study, review, other 
8.  Intervention 
9.  Comparator 
10.  Sample size 
11.  Sample country 
12.  Questionnaires 
13.  Preference elicitation technique 
14.  Preference-elicitation algorithm country 
15.  Other comments 
Table 2.4. Data extraction form. 
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2.5. Results 
 
 Term OVID CRD 
1. “Macular degeneration”.mp 30417 111 
2.  “Macular disease”.mp 1108 1 
3.  “Retinal disease”.mp 2974 3 
4.  “Macular $edema”.mp 14094 23 
5.  “Retinal vein occlusion”.mp 7225 9 
6. “Diabetic retinopathy”.mp 53073 77 
7.  1 or 2 or 3 or 4 or 5 or 6 96423 196 
8.  “Quality-adjusted life year*”.mp 24696 4067 
9.  “QALY””.mp 11968 3015 
10.  “EQ-5D”.mp 9020 587 
11.  “Euroqol”.mp 6382 234 
12.  “SF-6D”.mp 1215 45 
13.  “HUI”.mp 2943 55 
14. “Health utilities index”.mp 1518 92 
15. 8 or 9 or 10 or 11 or 12 or 13 or 14 40743 8095 
16. 7 and 15 383 82 
17.  Limit 16 to English lang. 383 N/A* 
18.  Limit 17 to 1990 - 2012 299 N/A* 
Table 2.5. Number of search results by search term. 
*limits set to each term in CRD 
 
Search details: 
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 Databases searched: MEDLINE, EMBASE and PsycINFO via Ovid and HTA 
and NHS EED via York CRD 
 Search dates: 01/01/1990 to 31/12/2012 
The results returned from the searches are detailed in Table 2.5. Titles and 
abstracts of the search results were screened. Figure 2.3 shows the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) scheme 
employed for screening search results.(69) 
Studies were included if they applied utility values for retinal conditions i.e. 
cost-utility studies for treatments, or if they reported utility values for retinal 
conditions or if they described methods to elicit them. 
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Figure 2.3. PRISMA scheme depicting record identification and screening. 
 
Identification
• Records identified through OVID. n = 299
• Records identified through CRD. n = 82
Screening 
(Level 1)
• Records screened. n = 381
• Records excluded at level 1. n = 199
• Record type (e.g conference abstract, 
letter, editorial). n = 47
• Therapy area (e.g. diabetes). n = 90
• Duplicate. n = 62
Eligability 
(Level 2)
• Abstracts screened. n = 182
• Records excluded at level 2. n = 88
• Record type (e.g. comment). n = 14
• Non-QALY-based. n = 23
• Duplicates. n = 51
Included
• Number of papers included. n = 94
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The 94 included studies were categorised as follows: 
 Economic model employing utility values, n = 53 
 Prospective trial collecting utility values, n = 10 
 Other study collecting utility values, n = 18 
 Review or discussion of utility values, n = 13 
The search showed that a wide range of techniques have been used to elicit 
utility values in AMD. These are described below and summarised in Table 2.6.  
Techniques that have been applied to estimate utility values in AMD for the 
calculation of QALYs have included direct elicitation from patients via the TTO, 
SG and contingent valuation, elicitation from members of the public using the 
TTO, generic preference-based questionnaires (EQ-5D, HUI-3, SF-6D), mapping 
from a condition specific questionnaire to a generic preference-based 
questionnaire (NEI VFQ-25 to EQ-5D), and a condition-specific preference-
based questionnaire (VisQoL). 
Among the studies that used direct preference elicitation from patients, a study 
by Brown et al., elicited utilities from a sample of 80 patients with AMD using 
the TTO and SG valuation techniques and associated these with different levels 
of VA.(48) The TTO values in this study were most frequently used to provide 
utility values for health states in economic models (see Appendix B for details 
of AMD CUA models). 
However, another study highlighted that different utility values were obtained 
depending on who they were elicited from. Stein et al. compared TTO valuations 
of AMD health states in patients, medical doctors and the general public. It 
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found that the general public and doctors rated the condition less severely than 
patients and argued that this suggested an underestimation of the severity of 
the condition on the part of members of the public and doctors.(70) 
A number of studies have derived utility values from preference-based 
questionnaires. Espallargues et al. compared several methods for eliciting 
utilities in a sample of AMD patients. The study administered the EQ-5D, SF-6D, 
HUI-3 and TTO.(58) The utility values from this study were applied to an 
economic evaluation of PDT for AMD based on CS health states by Bansback et 
al.(60) 
One mapping algorithm was identified which allows utility values to be derived 
from a non-preference based vision-specific questionnaire. Payakachat et al. 
developed a mapping algorithm to convert NEI VFQ-25 scores to EQ-5D utilities 
in AMD patients.(71) They recommended a CLAD short model over OLS or Tobit 
models. However, overlap was weak and, as of the date of the search, this 
algorithm had not been applied to an economic evaluation. 
Tosh et al. reviewed the performance of generic preference-based HRQoL 
questionnaires in measuring changes in vision. They found that the HUI-3 
seemed to perform better in some vision disorders, but the evidence on it and 
SF-6D is limited. The EQ-5D performed poorly in AMD and diabetic 
retinopathy.(14) 
Further evidence of the insensitivity of the EQ-5D in vision disorders was 
identified in Loftus et al.  The paper compared visual function and HRQoL in 
pegaptanib-treated patients with DMO. (30) They found statistically significant 
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improvements in visual function as measured by VA and in vision-specific 
quality of life as measured by the NEI VFQ-25 overall score, but no significant 
change in the mean change in utility from the EQ-5D. 
There remain unclear associations between visual function and HRQoL. VA has 
been noted to be weakly associated with utility and another measure of visual 
function, CS, has been shown to have an independent impact on utility.(59) 
In an attempt to solve the limitations with both direct patient elicitation and 
public tariff-based utilities, Czoski-Murray et al. developed utilities derived from 
members of the public who were asked to conduct a TTO while wearing contact 
lenses to simulate AMD.(72) These were used in the economic evaluation that 
was part of NICE’s HTA of ranibizumab and pegaptanib for AMD.(73) 
In terms of investigating the economic impact of treating different severities of 
disease: Javitt et al. developed an economic model to compare the cost-
effectiveness of treatment of nAMD with pegaptanib in cohorts of early, 
moderate and late disease.(74) They found that patients treated early incurred 
lower lifetime total direct costs than those treated later and that the ICER for 
early nAMD patients was around a third of that for late nAMD patients. However, 
NICE did not recommend pegaptanib for use in the NHS and recommended 
ranibizumab (another anti-VEGF) for treatment in only patients with vision 
worse than 6/12 (i.e. not in early patients).(73) 
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Instrument Category 
EQ-5D Generic preference-based 
SF-6D Generic preference-based 
HUI-3 Generic preference-based 
NEI-VFQ 25 Condition specific non-preference based (mapped) 
VisQoL Condition specific preference-based 
Time trade-off (TTO) Preference elicitation technique 
Visual analogue scale (VAS) Preference elicitation technique 
Contingent valuation Preference elicitation technique 
VF-14 Condition specific non-preference based (mapped) 
Visual acuity (VA) Visual function (mapped) 
Contrast sensitivity (CS) Visual function (mapped) 
Table 2.6. Summary of instruments used in utility measurement in AMD. 
 
2.6. Discussion 
Few clinical trials have incorporated measures suitable for calculating QALYs. 
All CUA models have been based on QALY weights derived from visual function 
measures of which most used a study that applied the TTO in AMD patients 
based on VA states.(48) 
Generic questionnaires, and particularly the EQ-5D, have been found to be 
insensitive. Elicitation of utility values for common vision disorders have used 
both perfect health and perfect vision as the anchor with several studies 
reporting CUA in vision years.(46) Valuations of AMD health states between 
patients, public and clinicians appear to vary.(70) 
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2.7. Interpretation and refined aims 
Four related research aims have been identified and refined to address the need 
to develop an improved method for measuring and valuing health benefits in 
vision disorders: 
 
2.7.1. How do widely used methods for deriving health state utility values 
in AMD perform and how can these methods be improved? 
The literature review highlights that methods for eliciting utilities for health 
states associated with vision problems have limitations in terms of the 
descriptive system employed. 
Generic preference-based questionnaires are used to measure health states in 
patients, the TTO is used to elicit utilities in patients. (Chapter 3). Following the 
identification of a paper describing the use of simulation contact lenses to elicit 
utilities via the TTO in members of the public, it was decided to also investigate 
this method as part of this research question.  (Chapter 3). 
A method for augmenting the descriptive system for informed valuation of 
health states is developed applying the TTO with additional disease information 
(Chapter 4). 
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2.7.2. Are non-health attributes important in AMD and how can they be 
incorporated into the cost-utility economic evaluation framework? 
QALYs are the most widely used framework for the economic evaluation of 
health technology. Yet, there may be non-health benefits associated with 
treatments from which patients derive welfare and vision may have an impact 
on aspects beyond health. For example, a treatment that has a more convenient 
delivery method may be valued by patients despite leading to an unchanged 
health gain. A method for incorporating these benefits into CUA is developed 
using a DCE (Chapter 5). A theoretical framework for assessing the benefits of 
improved patient decision making using decision support tools is also 
presented (Chapter 8). 
2.7.3. How is visual function associated with utility in AMD and how can 
the association be applied to economic evaluation? 
Many economic evaluations require the use of visual function variables as a 
surrogate for health state utility: generally because health state utility values 
have not been collected in a trial or because of the need to extrapolate the 
outcomes of a trial to a longer time horizon.  
There remain unclear associations between visual function and HRQoL. VA has 
been noted to be weakly associated with utility and another measure of visual 
function, CS, has been shown to have an independent impact on utility.(59) The 
impact on cost-effectiveness is investigated using a CUA model and a more 
comprehensive measure of visual function to extrapolate health state utilities in 
economic models is developed using mapping (Chapter Error! Reference source 
not found.). 
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2.7.4. What is the economic impact of treating AMD patients with good 
starting vision? 
The level of vision for which treatment is initiated may impact on the QALY gain 
generated by the intervention.(74) A CUA model comparing the initiation of 
treatment early or delaying treatment is developed to estimate the cost-
effectiveness of immediate treatment compared with current NICE guidance of 
delayed treatment (Chapter 7). 
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3. Measurement of health state utility values in vision 
This chapter investigates the performance of HRQoL questionnaires and 
valuation techniques currently used to elicit health state utility values for AMD 
in order to address the first part of research aim 1: How do widely used methods 
for deriving health state utility values in AMD perform and how can these methods 
be improved? 
3.1. Patient-reported outcome measures 
3.1.1. Introduction 
A systematic review of preference-based questionnaires in vision by Tosh et al. 
identified in the literature review (Chapter 2) describes concerns surrounding 
the performance of generic preference-based HRQoL questionnaires for 
measuring and valuing health states associated with AMD.(14) The authors 
found that the performance of the EQ-5D in visual disorders was inconsistent 
and there was limited evidence on either the HUI-3 or the SF-6D. 
It may be hypothesised that these questionnaires suffer from limitations in their 
descriptive systems and fail to contain sufficient information to reflect a 
patient’s health state, especially for diseases like AMD, which are neither painful 
nor life-threatening.(75) This would both make it hard for the patient to 
accurately express their health state and for the valuer to value that state. 
 Alternatively it could be that when patients classifying their health state, they 
misclassify the severity. Patients with chronic diseases are generally thought to 
report their health state less severely than those without the condition would 
expect due to the phenomenon of adaptation.(76) In AMD patients there is 
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evidence that this trend is reversed and that patients rate their health state 
more severely than the public.(70) 
This section compares four frequently used measures used to derive utilities for 
the estimation of QALYs: 
 The EQ-5D is a widely used HRQoL questionnaire with preferences 
derived from the general public.(18) With just 5 questions defining 
HRQoL and no mention of vision, there are concerns that it fails to 
provide a sufficient description of an AMD health state for accurate 
valuation by the public.(14) 
 The SF-36 is an alternative HRQoL questionnaire with a different 
descriptive system and associated valuation tariff (the SF-6D) that has 
shown greater sensitivity to changes in health with fewer ceiling effects 
in some conditions.(16) 
 The TTO is a preference-based technique allowing the patient to express 
preferences for their own health state on a utility scale bounded by 0 
(dead) and 1 (perfect health).(36) 
 The VAS is a non-preference-based technique allowing the patient to 
express their health state on a 0 to 100 scale between best and worst 
imaginable health.(77) 
Espallargues et al. previously reported health state utilities for AMD using a 
range of questionnaires including the three-level EuroQol EQ-5D and SF-
6D.(58)  The new five-level EQ-5D provides a more comprehensive 
descriptive system and may be more sensitive to differences in patients’ 
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level of visual disability.(78) Meanwhile, direct patient valuations of their 
health states have been produced by Brown et al. using the TTO.(48) 
 
3.1.2. Methods 
Sixty patients diagnosed with exudative (wet) or atrophic (dry) AMD with VA of 
0.3 logMAR (6/12) or worse in the better seeing eye were recruited from clinics 
at Moorfields Eye Hospital, London, UK. Patients were excluded if they had 
ocular comorbidities. An accurate sample size calculation could not be done 
prior to the start of the study given the lack of data comparing utilities from two 
different questionnaires. Post hoc sample size calculations are of limited value, 
but using the observed standard deviation of the difference between the EQ-5D 
and SF-6D equal to 0.22, a sample size of 60 gave a power in excess of 0.9 to 
detect a difference in utilities as small as 0.1. The power calculations was 
performed with the XSAMPSI routine in STATA (V12.1; Stata Corp LP, College 
Station, Texas, USA) with alpha = 0.05. 
The study was approved by the West London Research Ethics Committee (see 
Ethical approval) and followed the tenets of the Declaration of Helsinki. 
Patients gave informed written consent before taking part in the study. 
A trained interviewer administered the four instruments listed in Table 3.7 in a 
random order.  
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Instrument Preferences Valuation technique 
EQ-5D 
UK public (EQ-5D-5L interim 
value set) 
Time trade-off 
(preference-based) 
SF-6D 
UK public (UK valuation of SF-36 
US v1) 
Standard Gamble 
(preference-based) 
Time trade-off Patients’ Own 
Time trade-off 
(preference-based) 
Visual analogue 
scale 
Patients’ Own 
Visual analogue scale (non-
preference-based) 
Table 3.7. Health status questionnaires. 
 
The EQ-5D has five dimensions, each defined by a single question with five 
response levels. The five dimensions constitute a health state profile and the 
profiles were assigned a utility based on modelling from a large-scale survey of 
the UK general population using the TTO valuation technique.(20) 
The SF-6D is derived from items of the SF-36 questionnaire. It has six 
dimensions: physical functioning, role limitation, social functioning, bodily pain, 
mental health and vitality. It was valued using the SG valuation technique in the 
UK general population.(79) 
The TTO was a variant of the TTO used to value the EQ-5D developed by the 
University of York, UK.(80) Respondents were asked to value their own health 
state using a 10-year ping-pong technique (analogous to an adaptive staircase 
procedure) against perfect health and the result was converted to a utility. 
 64 
The EQ-5D VAS requires the respondent to rate their overall health on a scale 
between 100, the best imaginable health state, and 0, the worst imaginable 
health state. (EQ-5D, SF-6D, TTO and EQ-5D VAS questionnaires are presented 
in Appendix B)  
Sociodemographic information was also obtained from the participants. VA was 
taken from chart notes. While this is likely to be less accurate than if we had 
measured VA with a standardized protocol using ETDRS charts, the VA in the 
chart notes was the information available to the clinician at the time a decision 
was made regarding treatment. 
Repeated measures analysis of variance (ANOVA) was used to compare utilities 
among techniques. The contribution of VA to utility was assessed using 
regression. 
 
3.1.3. Results 
Of 60 patients recruited to the study, two withdrew before completing all of the 
questionnaires. Analysis was conducted on 58 patients with complete data. 
The sample was typical of AMD patients in a hospital setting. Mean age was 83.8 
(SD = 6.5) years and 67% (39) were female. Seventy nine percent of patients 
(46) had a diagnosis of wet AMD. The mean time since diagnosis was 7.0 (SD = 
6.2) years. Mean best-corrected VA in the better seeing eye was 0.65 (SD = 0.30) 
logMAR. 
Mean and median health state utility values are reported in Table 3.8 and the 
distributions for the four methods are shown in Figure 3.4. Mean EQ-5D utility 
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scores were 0.61 and skewed towards 1, perfect health (left skew). Two 
patients reported EQ-5D health states that resulted in utilities of states worse 
than death. SF-6D scores were centred around 0.63. The TTO had a mean of 0.48 
and a large standard deviation (0.41). VAS scores had a mean of 57 and 
displayed a right skew. 
 
Figure 3.4. Histogram of utility scores by instrument. 
 
Repeated measures ANOVA showed that there were significant differences in 
utilities derived with the four methods F(3, 33.6) = 5.21, p<0.01). Mauchly’s test 
indicated that the assumption of sphericity was violated (p < 0.05) therefore the 
degrees of freedom were corrected using Huynh-Feldt correction. Although 
ANOVA is quite robust to skew in the distributions of dependent variables, we 
repeated the analysis using the non-parametric Friedman test. The differences 
were still significant (p < 0.001)  
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Instrument Mean (SD) Median Interquartile range 
EQ-5D 0.613 (0.275) 0.657 -0.352 to 1.000 
SF-6D 0.628 (0.114) 0.640 0.340 to 0.920 
TTO 0.481 (0.411) 0.488 -1.000 to 1.000 
VAS 56.7 (21.8) 50.0 5.000 to 100.000 
Table 3.8. Frequencies of reported utility scores. 
 
The mean utility scores of the four instruments were compared using a set of 
orthogonal contrasts. The two patient-based instruments TTO and VAS gave 
significantly lower utilities than the two instruments based on public tariffs, 
TTO and VAS [F (1, 57) = 12.8, p<0.001]. The EQ-5D was not significantly 
different from the SF-6D [F (1,57) = 0.3, p>0.6]. 
Figure 3.5 illustrates the similarity between the EQ-5D and SF-6D (left panel) 
and between the EQ-5D and TTO (right panel). 
 
 67 
 
Figure 3.5. Comparison of methods for deriving public and patient preferences. 
 
3.1.4. Discussion 
These results showed no difference between utilities generated from the two 
generic HRQoL instruments tested, so public preferences for AMD health states 
appear to be independent of the two different descriptive systems used by the 
EQ-5D and SF-6D. Furthermore, there was no difference between patient 
preferences for their own health states when elicited by TTO or VAS, so patient 
preferences appear to be independent of the two techniques used. 
However, there was a significant difference between public and patient utilities, 
with patients classifying their own health state as more serious than the public 
reading a description of their state. Within the valuation task there appears to 
be an inherent difference when asked to value one’s own health compared to a 
hypothetical health state described by a HRQoL instrument. 
This study finds a much more marked difference between public EQ-5D and 
patient TTO utilities than Espallargues et al. Such a finding may be explained by 
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the fact that we used the new 5-level EQ-5D with its more comprehensive 
descriptive system compared to the 3-level EQ-5D used previously. 
The sample of patients may differ from the general public in sociodemographic 
characteristics. AMD patients are likely to be an older sample with more females 
than the general public sample used to establish the tariff. Patients with other 
diseases will differ from the general public in other ways. Consequently, the gap 
between public and patient preferences may differ not only due to the 
descriptive system, but also due to the different characteristics of the sample 
populations. 
The difference between patient TTOs and EQ-5D scores may also be due to the 
TTO not measuring HRQoL in this population. Non-health time-related concerns 
such for living alongside a partner have anecdotally been mentioned as 
important when AMD patients undertake a TTO exercise.(81) Furthermore, the 
age of the patient sample and prevalence of comorbidities may make it hard to 
imagine living 10 years in perfect health. The VAS is not a choice-based method 
and therefore not recommended for use CUA. Furthermore, its scale between 
perfect and worst imaginable health is not directly comparable with the other 
measures that anchor zero at death. 
The two forms of AMD (dry and wet) have similar impact on activities of daily 
living so we would expect no difference between the two groups. There was an 
insufficient number of patients with dry AMD recruited to assess this. However, 
a previous study by Bansback et al. identified no significant differences in 
utilities derived from the TTO or Health Utilities Index Mark-3 (HUI-3) between 
patients with wet or dry AMD.(59) 
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3.1.5. Conclusion 
This study demonstrates that public and patient preferences are different, 
making it important to have a clear rationale for the choice of perspective. This 
study is not designed to recommend whose preferences to use. This remains a 
choice for health care decision makers, taking account of whose preferences 
they wish to rely on when allocating resources.  However, the utilities derived 
by Brown et al.,(48) which are widely used in economic evaluation, are patient 
utilities and cannot be directly compared with utilities derived from public 
surveys. 
The size of the difference in health state utilities can be illustrated in QALYs by 
including the length of life component. If an AMD patient were to live in the 
mean health state for ten years, they would accumulate 6.1 QALYs according to 
the EQ-5D (public preferences), but only 4.8 QALYs according to the TTO 
(patient preferences). 
The implications for CUA of vision treatments are difficult to predict. It is the 
incremental change in QALYs before and after treatment compared to current 
standard care that is important when assessing cost effectiveness. Put another 
way, the methodology is distribution neutral and an improvement in health 
state utility for a moderately ill patient is equivalent to the same improvement 
in a severely ill patient.(82) However, given the different starting position on 
the scales, we would hypothesize that changes would be different. Furthermore, 
there is an emerging body of evidence that preferences for resource allocation 
are driven by the starting position on the scale, with some surveys suggesting 
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preferences for treating groups of patients with more severe disease ahead of 
those with less severe disease.(83) 
Future work is needed to isolate the impact of the descriptive HRQoL system on 
preferences in order to determine if the differences in preferences identified in 
this chapter are due to a lack of information for public valuations or an inherent 
difference in perspective of patients and general public in their preferences for 
health states. From this work, given the two descriptive systems tested gave 
similar scores, the latter appears more likely. 
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3.2. Simulating health states 
3.2.1. Introduction 
An alternative approach to the use of PROMs to measure health states for 
valuation has been to create a simulation of AMD in members of the general 
public and ask them to value the health state that they experience. 
Treatments for AMD and diabetic macular oedema (DMO) have been appraised 
by NICE in recent years.  Appraisals of treatments for AMD and DMO were based 
on utilities from Czoski-Murray et al. which conducted a contact lens simulation 
of AMD.(72) In the study, members of the general public wore a contact lens 
with a central opacity that was meant to simulate the patient’s view of the world 
through a central scotoma. Participants then completed a series of HRQoL 
questionnaires and the TTO to produce utility values associated with different 
levels of AMD severity. These health state utility values were applied to health 
economic models based on levels of VA (which represents a person’s ability to 
resolve fine detail). 
NICE Multiple Technology Appraisal 155 recommended ranibizumab for the 
treatment of AMD.(2) Following appeal and rapid review of Single Technology 
Appraisal 237, ranibizumab was recommended as an option for treating visual 
impairment due to diabetic macular oedema if the eye has a central retinal 
thickness of 400 micrometres or more at the start of treatment and the 
manufacturer provides ranibizumab with the discount agreed in the revised 
patient access scheme (PAS).(84) 
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The performance of the contact lenses was assessed in order to assess the 
validity of this simulation. Both of these conditions can, in advanced cases, lead 
to the development of an absolute scotoma (a complete absence of retinal 
function) in the central retina. Broadly speaking, scotomas caused by AMD, DMO 
and similar diseases are a consequence of abnormalities at a retinal level.  In 
advanced cases, these retinal abnormalities lead to dysfunction of the rod and 
cone photoreceptors in a confined area of the retina (the macula) which results 
in a blind spot at or near fixation. This blind spot greatly interferes with reading 
and recognizing faces and object. In contrast, a contact lens sits on the cornea, in 
front of the nodal point of the eye.  Opacities on a contact lens would be 
expected to cause an overall reduction in the amount of light that reaches the 
retina, but not to cause a blind spot (see Figure 3.6 and Figure 3.7). While this 
reduction in retinal illumination may affect vision, the impairment is far less 
debilitating than that caused by a blind spot on the visual axis.  
 The effect of the opaque contact lenses was measured on five healthy 
volunteers who underwent a standard battery of vision tests, comparing their 
performance to the performance of actual AMD patients with real central 
scotomas. 
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Figure 3.6. Ray diagram illustrating the optical effect of a contact lens with an opaque centre. In 
figure 3.6A the object (an arrow, left) is focused on the retina (right) with a plus lens (the 
crystalline lens and cornea, centre). Rays from all points in the object will be imaged onto the 
retina. In figure 3.6B, a contact lens is placed in front of the cornea. The contact lens has an opaque 
central zone which blocks some rays emanating from the object reaching the image. But some rays 
from all parts of the object still reach the retina. The retinal image is darker with the occluder and 
the image is blurred somewhat, because the optics at the edge of the crystalline lens have worse 
aberrations than the central optics, but the retinal image is complete and there is no scotoma. 
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Figure 3.7. A simulated image of a logMAR visual acuity test is shown without (A) and with (B) an 
occlude showing a reduction in luminance of the test chart, but no central opacity.. 
    
 75 
3.2.2. Methods 
Five control subjects with good VA and no history of eye disease were recruited 
from colleagues and staff of the Institute of Ophthalmology.  
The study was approved by the University College London ethics committee 
(see Ethical approval), informed consent was obtained from all participants 
prior to data collection, and the study conformed to the Declaration of Helsinki. 
A soft contact lens with an opaque pupil was selected for all participants based 
on keratometry readings.  The lens design was similar to that used in the Czoski-
Murray et al. study.  In all cases the lens was a 67% water content afocal soft 
contact lens of diameter 14.5mm, with a 6mm black central pupil (Ultravision 
CLPL, Leighton Buzzard, UK).   
All vision tests were performed monocularly with and without the contact lens 
in place.  The test eye was selected by each participant. 
The vision tests included distance VA (measured at 4 m using a standard ETDRS 
acuity chart (Lighthouse Low Vision products, New York, USA)) and CS 
(measured using either the MARS chart at 40cm or the Pelli-Robson chart at 
1m).   
Microperimetry was performed using the MAIA microperimeter (CenterVue, 
Padova, Italy).  This is a scanning laser ophthalmoscope based perimetry system 
which performs visual field testing whilst simultaneously imaging the retina, 
enabling the retinal location of each visual field position to be controlled.(85)  
68 points were tested over the central 10 degrees of retina, spaced at 2° 
intervals.  Retinal sensitivity was measured using white Goldmann III targets, 
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presented for 200 ms, and thresholds were calculated using an adaptive 
staircase algorithm. Fixation stability was measured as the area of a bivariate 
contour ellipse encompassing 95% of fixation points. 
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3.2.3. Results 
The contact lens reduced VA by an average of 17 letters (median logMAR = -
0.34 ; p< 0.01) and reduced CS by an average of 7 letters (median logCS = 0.36 ; 
p < 0.01)  (Table 3.9). Fixation stability was not affected by the contact lens 
(p>0.2). 
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Table 3.9. Results of visual tests for each participant, with and without simulation contact lens. 
*CL: contact lens. IQR: interquartile range. 
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Figure 3.8 shows microperimetry plots of retinal sensitivity for each 
participant. The figures on the left (“a” panels) show data without the contact 
lens and the figures on the right (“b” panels) are with the contact lens. “Hotter” 
colours (yellow, orange, red) indicate poorer retinal function and “cooler” 
colours (green, blues) show areas with better retinal sensitivity.  It can be seen 
that the contact lens reduces retinal function over the central retina but does 
not produce any central region of absolute scotoma (with sensitivity less than 0 
dB). Median retinal sensitivity without the contact lens was 27.0 dB, and 18.1 
dB with the contact lens. The median difference was -8.3 dB. 
 For comparison, a microperimetry plot for a subject with AMD is shown in 
Figure 3.9.  It can be seen that this individual has a large area with no retinal 
function (sensitivity less than 0 dB, black circles on Figure 3.9). 
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Figure 3.8. Microperimetry images for each participant with and without simulation contact lens. 
 81 
 
Figure 3.9. Microperimetry image for a subject with age-related macular degeneration.  
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3.2.4. Conclusion 
A contact lens with central opacity reduces retinal illumination across the 
macula which reduces VA and CS.  It causes a general reduction in retinal 
sensitivity but importantly does not create any area of absolute scotoma.  
Therefore, a contact lens with a central opacity does not accurately simulate the 
effects of advanced AMD. 
Whether this will impact on the accuracy of the derived utility values is 
dependent on the strength of the association between VA and utility across eye 
conditions. 
Most studies of vision and utility have shown that utility values worsen as visual 
impairment increases, although different conditions may affect vision 
differently, for example some conditions impact on visual field whereas others 
affect visual acuity. 
It has been shown that VA is weakly associated with utility and that other 
aspects of visual function such as CS and visual field have a large impact on 
utility.(59, 86) A drop in VA due to a central scotoma in AMD has a different 
impact of quality of life and consequently utility than the same drop in VA due to 
cataract. 
Brown et al. reported utility values using the TTO in AMD, cataract and diabetic 
retinopathy by levels of VA. For the same level of vision (20/70-20/100) 
patients with AMD reported a mean utility of 0.62, patients with cataract 
reported a mean utility of 0.71 and patients with diabetic retinopathy reported 
a mean utility of 0.78.(87) 
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Given the more severe impact of reduced acuity on utility in patients with AMD 
compared with cataract, it can be expected that a true simulation of AMD would 
lead the public to rate AMD more severely than predicted by contact lens. 
An error of the magnitude of 0.09 on the utility scale is a major shift in a disease 
that impacts on QALYs through long term decrease in utility, although the 
impact on the incremental cost-effectiveness ratio (ICER) of this difference is 
difficult to quantify. 
Evidence from the DMO ERG report suggests the ICER is sensitive to the utility 
values used. ICERs ranged from £16,585 to £39,712 in sensitivity analysis based 
around the Czoski-Murray et al. utility values, compared with £21,504 to 
£50,879 for the same sensitivity analysis based around Brown et al. utility 
values. The cost-effectiveness threshold is generally considered to be between 
£20,000 and £30,000 per QALY. Both analyses included the Novartis PAS 
discount, so represented the actual cost to the NHS.(88) 
It could be argued that the generalised reduction in sensitivity induced by the 
contact lens is akin to a relative scotoma in early AMD.  However, this was not 
the aim of the original research papers, which was designed to simulate a 
central scotoma.(72) Further, at the stage of AMD associated with reduced VA, 
some absolute central scotoma is to be expected. 
A well reported functional consequence of AMD is reduced fixation stability.(89)  
Poor fixation stability is known to be associated with poorer visual function, 
particularly for reading.(90) Reduced fixation stability was not identified by the 
contact lens simulation, further limiting its applicability to true macular disease.  
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This study was conducted in a sample of five participants.  Although the sample 
size was small, the results were consistent, with all observers showing a drop in 
acuity and contrast sensitivity, but no scotoma. The use of “forced-choice” 
testing procedures increases the reliability of the tests and reduces the 
opportunity for subjects to consciously influence the results. 
How should central vision loss be simulated?  Spectacles with opacities on are 
not a valid option as eye movements will alter the retinal position of the opacity.  
Although contact lenses seem like an attractive option to simulate vision loss, 
we have shown that this does not create a central scotoma.  The most 
appropriate way of simulating a scotoma in people with good vision is to use 
feedback from an eye tracking system.  These devices display an image on a 
computer screen whilst simultaneously measuring the position of the eye.  
Software can produce a scotoma at the region of the image corresponding to the 
centre of gaze.  These systems have been used in research settings (91, 92) but 
have not, to date, been used to elicit utility values for AMD states in a public 
sample. A simulation is likely to be the most accurate way for people with good 
vision to imagine the health state of a scotoma caused by AMD. However, the 
simulation will still have limitations since participants are unlikely to be able to 
experience the simulation for long enough to imagine the long term impact of 
the condition on daily activities in a real world setting. Further, the simulation 
of a single state would not allow the participant to imagine the progressive 
nature of the condition. 
Alternatively, one could return to the reason for the use of the simulation. The 
deviation from generic HRQoL questionnaires to derive health state utilities was 
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due to concern that standard questionnaires were not sensitive to changes in 
visual function due to limitations with the descriptive system. Future work to 
enhance the sensitivity of generic questionnaires may again place vision 
disorders on a common health state utility scale required for economic 
evaluation. 
A contact lens with a central opacity does not simulate a retinal scotoma that is 
characteristic of diseases of the central vision like AMD. Opaque contact lenses 
reduce retinal illumination which leads to a reduction in VA and CS, but the 
overall dimming effect bears little resemblance to a central scotoma that is the 
hallmark of AMD 
The association with a lower level of VA is not AMD-specific and contact lens 
utilities could represent many causes of visual impairment. The VA association 
has been shown to be different across disorders, therefore public valuations 
using this method may misinform the public. 
The use of these utility values in economic evaluations may lead to an incorrect 
estimation of the cost effectiveness of treatments for AMD and other eye 
diseases that cause central scotomas. 
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4. Valuation of health state utility values in vision 
This chapter investigates the impact of information on the valuation of health 
states by the general public. The descriptive system of the EQ-5D is augmented 
with disease information to derive health state utility values for AMD in order to 
address the second part of research aim 1: How do widely used methods for 
deriving health state utility values in AMD perform and how can these methods be 
improved? 
 
4.1. Introduction 
It is widely accepted in the health economics literature that the general public 
should value health states.(3) As payers in a tax-funded health system, it is 
considered right that the public’s preferences are taken into account when 
allocating health care resources. Furthermore, the public offers an unbiased 
view of health states, unaffected by the condition they are valuing. 
Having said this, there are serious information problems within health, which 
may mean the public lack information about health conditions. Indeed, the 
Washington Panel on Cost Effectiveness argued that ‘…the best articulation of 
society’s preferences for a particular state would be gathered from a 
representative sample of fully informed members of the community’.(8)  
In the UK, NICE currently recommends generic preference-based health-related 
quality of life questionnaires, namely, the EQ-5D, for use in CEA.(2) The EQ-5D 
UK value set was obtained from a population of ‘uninformed’ general public by 
conducting TTO valuation tasks on EQ-5D health states.(80) 
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Concerns have been raised about the performance of the EQ-5D in some health 
conditions, including vision-loss, as demonstrated in the previous chapter of 
this thesis.(14, 93) Information provided by the questionnaire may give the 
uninformed valuer limited information on what it is like to live with a disease 
and how one may adapt to achieve high quality of life despite what may initially 
appear to be disabling limitations of a chronic condition.(76) This information 
problem may be accentuated by the relatively short nature of generic 
preference-based HRQoL questionnaires used to value health states: the EQ-5D-
5L questionnaire consists of 5 questions each with 5 levels. 
Vision-loss is one such example where lack of information about the condition 
and the process of adapting to it may not be fully captured in the EQ-5D health 
state.(14, 58) A study in AMD patients found that patients value their health 
more severely than the general public using the TTO.(70) 
Recognising these limitations, contact lenses simulating AMD have been tried as 
a method of informing the public about AMD prior to valuing the health 
state.(72) Indeed, health state utilities derived from this approach were used in 
NICE’s technology appraisal of treatments for AMD.(73) However, contact 
lenses do not simulate the loss of central vision that typically occurs with AMD 
as demonstrated in Chapter 3 of this thesis. Furthermore, wearing lenses for a 
short time may not accurately simulate the long-term effects of living with a 
chronic disease.(94) 
Perhaps most importantly, if decision-makers wish to maintain cross-program 
comparability for CUA, the method of informing for health state valuation 
should be as standardised as possible across conditions. Simulating an eye 
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condition may be technically feasible, but simulating a disease in the general 
public would be challenging and ethically undesirable in many other conditions. 
For this reason, it can be argued that the provision of information prior to a 
valuation task using a generic HRQoL instrument is the most promising way to 
close the information gap if bias can be avoided. 
A study by Rowen et al. investigated the impact of providing different disease 
labels on valuations. (75) The study investigated the effect of labelling on health 
state valuations in cancer and irritable bowel syndrome (IBS). It found no 
significant differences between health state values when the description 
contained no label or an IBS label. However, a cancer label affected health state 
values and the impact depended on the severity of the state: values were 
significantly lower when labelled for worse states, but there was no significant 
difference for mild states.(75) They suggested that people may bring their 
preconceptions about a condition to the valuation task. 
The aim of this study was to investigate the effect of different types of 
information on valuations of AMD heath states by the UK general public. This 
study takes a single condition where there are thought to be information 
problems and seeks to determine if the framing of information influences 
valuations of EQ-5D health states by the general public. 
The study assessed how different types of information affect valuation by 
comparing no information, a label and patient descriptions. It also tested how 
the way this information was presented affects valuation by including two 
different patient descriptions. 
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4.1.1. Pilot 
The survey was piloted in a convenience sample. 40 members of the general 
public each completed TTO tasks on 4 health states (Table 4.12) accompanied 
by varying levels of information about AMD generating 150 health state utility 
values after missing data. The four information levels were: 
 Group 1: Unlabelled AMD patient EQ-5D profiles. (No Information). 
 Group 2: Short objective label of AMD from the NHS Choices website 
followed by the same 4 AMD patient EQ-5D profiles. (Label). 
 Group 3: Short objective label of AMD and a patient description of their 
quality of life with the condition followed by the same 4 AMD patient EQ-
5D profiles. (Patient Description) 
 Group 4: Short objective label of AMD and a patient description of their 
quality of life with the condition and information on how a patient might 
adapt to life with AMD followed by the same 4 AMD patient EQ-5D 
profiles. (Adaptation) 
Participants were randomly drawn into one of four information groups prior to 
beginning the task resulting in 13, 7, 7 and 13 participants entering groups 1, 2, 
3 and 4 respectively. There were more females than males in the sample and the 
mean age was slightly lower than the UK average (Table 4.10). 
 
  
 91 
Group 
(n=40) 
1 (n=13) no 
information 
2 (n=7) label 3 (n=7) patient 
description 
4 (n=13) 
adaptation 
Mean age 
(SD) 
36.8 (11.1) 38.1 (12.4) 29.1 (6.7) 35.7 (9.8) 
Gender F: 9 M: 5 F: 6 M: 1 F: 5 M: 2 F: 6 M: 7 
Table 4.10. Pilot demographic information 
 
The public TTO valuations for each health state by group are summarised in 
Table 4.11.  Utilities were generally skewed towards 1.0 (left skew). While due 
to the small sample, statistical significance cannot be inferred from the pilot 
results, respondents generally valued the health state similarly to the EQ-5D 
tariff as would be expected since the TTO valuation of an EQ-5D profile by a 
sample of the general population used in the study follows the methods used to 
obtain the tariff (with the exception of the elicitation method for this study 
being online). A trend for respondents to value health states accompanied by a 
label or a patient description more severely may be observed across health 
states. While adaptation information caused respondents to value the health 
state less severely than the social tariff. These trends agreed with the 
hypothesis that additional information caused respondents to change their 
valuation and that the type of information is important to determine the 
direction and magnitude of effect. 
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*EQ-5D-5L UK interim value set. 
  
Table 4.11. Pilot utility values by information group and health state. SD = standard deviation. 
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Information from pilot for design of main study 
Based on feedback obtain through discussion of a paper describing the results 
of the pilot at the Health Economists’ Study Group meeting in Oxford (June 
2011), it was determined that providing information on adaptation to AMD was 
challenging due to the difficulty separating out a treatment from the 
psychological process. For example, a personal decision to use a white cane may 
make movement easier and so improve the mobility domain of HRQoL. 
However, the cane itself is a treatment. Consequently, it was decided that for the 
full study, the adaptation information would be replaced by a second patient 
description in order to test the stability of preferences to different wording of 
the same type of information. 
Feedback from the pilot also led to the addition of a question to test that 
respondents had understood the information that they had read. In the full 
study a multiple choice question was included at the end of the survey to test 
what respondents understood about AMD. 
In the full survey, the four AMD health states, the label and the patient 
description were retained, and an additional patient description was 
substituted in place of adaptation 
 
4.2. Methods 
550 members of the general public were recruited via an online survey panel. 
Recruitment quotas were set for age, gender, location and socio-economic group 
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in order to obtain a sample that was representative of the English general public 
for these characteristics. 
Participants were randomised to 4 groups to receive different levels of 
information about AMD before completing TTO valuations on AMD patient 
health states elicited in a prior patient study described in Chapter 3 (Table 
4.12). 
 Group 1 was asked to perform a series of 4 TTOs on 4 unlabelled AMD 
patient EQ-5D profiles. (No Information). 
 Group 2 read a short objective label of AMD from the NHS Choices 
website before being asked to perform a series of 4 TTOs on the same 4 
AMD patient EQ-5D profiles. (Label) (56). 
 Group 3 read a short objective label of AMD and a patient description of 
their quality of life with the condition before being asked to perform a 
series of 4 TTOs on the 4 AMD patient EQ-5D profiles. (Patient 
Description A) (95) 
 Group 4 read a short objective label of AMD and a patient description of 
their quality of life with the condition before being asked to perform a 
series of 4 TTOs on the 4 AMD patient EQ-5D profiles. (Patient 
Description B) (56) 
The two descriptions were selected to contain the common features of AMD, 
while presenting the information in slightly different ways. Both describe how 
the disease affects central vision and does not cause complete blindness, how it 
affects reading, driving, recognizing faces and aspects of depression or coping 
with the disease. In terms of differences, the first profile describes the condition 
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as ‘age-related macular degeneration’ whereas the second describes the 
condition as ‘macular degeneration’. The first profile uses a third person 
description with quotes from the patient, whereas the second profile is a first 
person description. (Box 4.1) 
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Health State 1 
(11112), 0.88* 
Health State 2  
(31211), 0.82* 
Health State 3 
(31312), 0.76* 
Health State 4 
(21513), 0.43* 
I have no problems 
in walking about 
 
I have moderate 
problems in 
walking about 
I have moderate 
problems in walking 
about 
I have slight 
problems in 
walking about 
I have no problems 
washing or dressing 
myself 
I have no 
problems washing 
or dressing myself 
I have no problems 
washing or dressing 
myself 
I have no 
problems washing 
or dressing myself 
I have no problems 
doing my usual 
activities 
I have slight 
problems doing 
my usual activities 
I have moderate 
problems doing my 
usual activities 
I am unable to do 
my usual activities 
I have no pain or 
discomfort 
 
 
I have no pain 
or discomfort 
 
 
I have no pain or 
discomfort 
 
 
I have no pain 
or discomfort 
 
 
I am slightly anxious 
or depressed 
 
I am not anxious 
or depressed 
I am slightly anxious 
or depressed 
 
I am moderately 
anxious or 
depressed 
Table 4.12. Patient EQ-5D profiles selected for valuation by the public. 
*Utility scores derived using the EQ-5D-5L UK interim value- set. 
 
An online TTO programme was developed to collect public utility values on 
patient health states. A screenshot of this tool is provided in Appendix B). The 
TTO was consistent with the York Measurement and valuation of Health (MVH) 
study (including 10-year timescale, ping-pong technique, certainty of health 
over time period, slider props).(80) 
The programme consisted of the following: 
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- An introduction screen 
- Socio-demographic questions 
- An introduction to the TTO technique 
- Information about AMD (Groups 2, 3, 4 only) 
- 4 TTOs on 4 patient EQ-5D health states (the state was labelled as 
‘macular degeneration’ in Groups 2, 3, 4, and unlabelled in Group 1). 
A question at the end was included for Groups 2, 3, 4 to test participants’ 
understanding of AMD to confirm if they had read the information carefully. The 
time that participants took to complete the survey was recorded and a 
minimum completion time of 8 minutes was set to exclude participants who did 
not read the information. 
Each participant completed TTOs on the same four EQ-5D profiles. The order in 
which health states were presented was randomised. The EQ-5D profiles were 
selected from AMD patients who had reported no significant comorbidities in a 
previous study so as to present to the public health states that could plausibly 
be due to AMD in an otherwise healthy individual. The health states are 
described in Table 4.12. 
Utility data was non-parametric, therefore Kruskal–Wallis one-way analysis of 
variance tests were used to estimate the impact of levels of information and 
health states on utility values. Analysis was conducted using Stata 12.1 
(StataCorp). 
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Box 4.1. Health state information provided to respondents prior to 
valuation tasks. 
Group 2 (label) 
The health states that you are about to be presented with describe a person with macular 
degeneration (although please note that this condition may not be the only cause of their health 
status). Please read this description of macular degeneration carefully. 
Macular degeneration is a painless eye condition that leads to the gradual loss of central vision 
(the ability to see what is directly in front of you). Central vision is used while: 
• reading 
• writing 
• driving 
Macular degeneration does not affect the peripheral vision, which means that the condition will 
not cause complete blindness. The peripheral vision is sometimes known as "side vision". 
 
Group 3 (patient description A) 
The health states that you are about to be presented with describe a person with macular 
degeneration (although please note that this condition may not be the only cause of their health 
status). Please read this description of macular degeneration carefully. 
Macular degeneration is a painless eye condition that leads to the gradual loss of central vision 
(the ability to see what is directly in front of you). Central vision is used while: 
• reading 
• writing 
• driving 
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Macular degeneration does not affect the peripheral vision, which means that the condition will 
not cause complete blindness. The peripheral vision is sometimes known as "side vision". 
 
Here is a description by a patient of what it may be like to live with macular degeneration 
Shirley’s granddaughter Caroline is four years old, and for most of her life, her grandmother has 
had age-related macular degeneration (AMD), a condition that causes a loss of central vision. 
“She always wanted to know what was wrong with Nana,” says Shirley.  
For the longest time, Caroline couldn’t understand why her grandmother had trouble getting 
around. “I was always bumping into things,” says Shirley. “And I didn’t dare hold her when she 
was a baby – I was afraid of dropping her.” 
AMD also made it difficult for Shirley to see Caroline’s face. “I would look at someone and see 
eyes on each side, but I couldn’t see anything in the middle. There was no nose or mouth or 
anything.” 
Shirley first began to notice her vision was changing 10 years ago. “A road would look like it was 
hilly when in fact it was straight, and things like the edge of the stove or a painting would look 
like they were wavy. It was the strangest thing.”  
Her vision loss progressed rapidly, and soon she had to give up driving and reading, two 
activities that had been very important to her. Losing the ability to drive forced Shirley into 
retirement, because she no longer had a way to get to her job. And her long-time, three book-a-
week habit fell by the wayside. 
 “I got very depressed.” she recalls. 
 
Group 4 (patient description B) 
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The health states that you are about to be presented with describe a person with macular 
degeneration (although please note that this condition may not be the only cause of their health 
status). Please read this description of macular degeneration carefully. 
Macular degeneration is a painless eye condition that leads to the gradual loss of central vision 
(the ability to see what is directly in front of you). Central vision is used while: 
• reading 
• writing 
• driving 
Macular degeneration does not affect the peripheral vision, which means that the condition will 
not cause complete blindness. The peripheral vision is sometimes known as "side vision". 
 
Here is a description by a patient of what it may be like to live with macular degeneration 
"I found out I had macular degeneration when I went to the optician for some new glasses. The 
optician examined my eyes and told me: "You’ve got macular degeneration, but don’t worry, you 
won’t go completely blind."   
"It was a surprise. My mother had suffered from macular degeneration, but it hadn’t occurred to 
me that I might have it one day. The signs had probably been there, but I hadn't noticed them. I’d 
been doing a lot of numerical work and was having problems reading the numbers 6, 8 and 3. I 
had to concentrate very hard in order not to get them muddled up. 
"At first it wasn’t too much of a problem. My right eye was affected, and it stayed that way for 
three years. But when I began to get macular degeneration in my left eye, I had to give up 
driving. That was hard – a part of my independence had gone. Luckily, my husband drives, so I 
can still get around, but it was a difficult time. 
"In the last few years, the macular degeneration has progressed more rapidly. I’ve had to give up 
a number of things I really liked doing, such as calligraphy and tapestry. Reading has become 
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difficult, so I now listen to talking books. I’ve also been in some embarrassing situations when 
I’ve passed friends in the street and not recognised them. 
 
Adaptation information (used in pilot study only) 
There are adjustments that can be made to adapt to life with macular degeneration: 
* Getting around 
You will be able to rely on peripheral or remaining vision, hearing, or the white cane to provide 
guidance. Devices such as telescopes can be used to identify street signs and addresses. 
* Recognising faces 
Arrange for a friend or peer to accompany you. It may be easier for them to explain to people 
that their smiles and waves can’t be seen and to encourage them to identify themselves when 
they want to talk to you. 
* Usual activities (reading and driving) 
Driving is one activity that people with severe vision loss find extremely hard to give up. 
However, activities such as reading can continue with a little patience and adjustment. For 
instance, large-print books or a magnifier may help with reading. Talking books are an excellent 
substitute when reading becomes too difficult. 
 
 
4.3. Results 
550 members of the general public completed 2,200 TTO tasks. The sample had 
a mean age of 45.7 (all >18) and was representative of the general population 
for gender and socio-economic group. Participants lived in England in order to 
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represent the preferences of the group that should inform decision-making in 
the English NHS. Groups were similar with respect to these characteristics 
(Table 4.13). 
 
  
 103 
 
No 
informatio
n (n=136) 
Label 
(n=139
) 
Patient 
descriptio
n A 
(n=137) 
Patient 
descriptio
n B 
(n=138) 
All 
(n=550
) 
ANOV
A P 
value 
by 
group 
Mean age, years (SD) 
45.1 (13.5) 
46.3 
(13.8) 
45.3 (14.2) 45.9 (14.4) 
45.7 
(14.0) 
0.88 
Age, % 18-40 39% 40% 42% 40% 40% 
 41-65 57% 48% 49% 47% 50% 
Over 65 4% 12% 9% 13% 9% 
Gender: Female, % 52% 50% 56% 58% 54% 0.56 
Activity, 
% 
Employed/self
-employed 
83% 76% 72% 83% 79% 
0.03 
Full-time 
education 
3% 2% 4% 0% 2% 
Retired 3% 6% 3% 6% 4% 
Looking after 
the home 
1% 1% 1% 1% 1% 
Long-term 
illness/disable
d 
4% 7% 8% 1% 5% 
Unemployed 6% 8% 12% 9% 9% 
Education: Degree level or 
above, % 
37% 39% 40% 41% 39% 0.83 
Mean own health state 
utility* (SD) 
0.83 (0.19) 
0.79 
(0.22) 
0.79 (0.24) 0.81 (0.20) 
0.81 
(0.21) 
0.31 
Correct understanding, % 
- 59% 64% 51% 
58% 
(n=414) 
 
Mean time to complete, 
min.s (SD) 
13.38 (8.32) 
12.43 
(6.06) 
13.18 
(6.03) 
13.26 
(9.32) 
13.16 
(7.35) 
0.78 
Table 4.13. Respondent characteristics. 
*EQ-5D 5L UK value set 
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The public TTO valuations for each health state by group are summarised in 
Table 4.14. Mean health state utilities were lower in the groups receiving 
patient profiles than in the groups receiving no information or the AMD label 
(0.65 and 0.66 vs. 0.70 and 0.71 respectively). Median values followed the same 
trend (0.88 and 0.88 vs. 0.83 and 0.83 respectively). TTO valuations were 
similar for Groups 3 and 4 (two versions of patient profiles) so these two groups 
were combined for further analysis. 
 
 
Figure 4.10. Health state values by group. 
 
Kruskal–Wallis one-way analysis of variance tests were used to estimate the 
impact of levels of information and health states on utility values since utilities 
0.55	
0.60	
0.65	
0.70	
0.75	
0.80	
No	info	 Label	 Pt	descrip on	A	 Pt	descrip on	B	
11112	
31211	
31312	
21513	
All	health	
states	
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were non-parametric. (Table 4.14). Pooled across all four health states, 
information led to different utility values (p<0.1). 
Median health state utility values for the information Groups 2, 3, 4 (label and 
patient description) were compared to Group 1 (no information). Neither of the 
information groups were significant when compared with Group 1. 
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a. By group 
 
b. Groups 3 and 4 combined into 3 
 
Figure 4.11. Means and CIs for health state utilities averaged across four health states.  
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Table 4.14. Health state utility values by group. SD = standard deviation, IQR = interquartile range. 
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4.4. Conclusion 
No differences were found in health state values with and without an AMD label. 
Mean health state utility in the label group was 0.71 compared with 0.70 in the 
no information group. AMD does not have a direct mechanism of action to 
increased mortality and this lack of a ‘dread’ risk factor may explain how a label 
does not change preferences for health states associated with AMD. 
Furthermore, we suspect that AMD is not well known as a condition among the 
general public, so the condition itself will not elicit strong emotions.  
These results are consistent with the findings by Rowen et al. relating to 
labelling milder health states, which found that there was no significant 
difference for milder health states associated with cancer or for health states 
associated with IBS.(75) 
There was a trend (not significant) towards lower utility in the patient 
description groups when compared with no information (0.70 vs 0.66 and 0.65 
respectively). This trend was consistent across all health states and patient 
profiles except one (31312 and patient description B). The two patient 
descriptions led to similar health state utilities across health states (0.66 and 
0.65 respectively) suggesting that the wording of the profile had little impact on 
the valuation. 
The number of participants in Groups 2, 3 and 4 who correctly answered the 
knowledge test was low (58%). Such a situation may have contributed to the 
finding of no significant difference between groups. Adjusting for this by 
excluding participants who answered the question incorrectly resulted in no 
 109 
significant difference, although this adjustment also reduced the statistical 
power. 
Knowledge of AMD may be influenced by having friends or family with the 
condition. This information was not gathered in the demographic details, 
although it could be expected that the random selection of the sample as 
representative of age and gender should not have led to one group having more 
knowledge than others. 
The range of utilities associated with vision run across a small range. The 
difference between normal vision and severe sight impairment (blindness) is a 
little over 0.1 on the utility scale derived from the EQ-5D, with wide standard 
errors.(58) In this context, additional information can be expected to lead to a 
small change in utility, which this study may not have had the power to detect. 
The difference between the mean utilities of Groups 1 and 4 averaged across the 
four health states was 0.047. Even small differences in health state utility may 
lead to a different outcome for the cost effectiveness of an AMD intervention as 
the health gains are relatively small, but run for several years. 0.05 shift 
downwards from no information (0.70) to patient descriptions (0.65), 
represents almost half of the range of vision on the EQ-5D utility scale. 
Therefore while differences of the magnitude detected in this study did not 
reach statistical significance, they could have major economic implications for 
resource allocation decisions if central utility values were applied to cost 
effectiveness models. 
Group 1 (no information) provided mean health state utility values that were 
different from the EQ-5D UK value set. The survey was completed online in 
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order to generate a large sample size rapidly, whereas the EQ-5D values are 
based on the MVH project, which used face-to-face interviews. There are 
questions of comparability between TTO elicitation exercises completed face-to-
face and online.(96) In this study as we seek to compare between subjects all 
using the online program, this should not impact on the internal validity of the 
results.  
The framing of information influences health state valuations in AMD. The 
choice of preferences is a normative decision, but the choice of informed or 
uninformed preferences has the potential to impact on cost-effectiveness 
decisions in vision. 
The use of an AMD label in the valuation task does not lead the public to 
different preferences for health states. Taken with the results of other studies, 
labelling does not seem to influence valuations in mild health states. 
There may be a trend that reading AMD patient descriptions leads the public to 
value health states more severely. While the differences detected were not 
statistically significant, the magnitude would be sufficient to influence economic 
evaluations. 
This study raises the prospect that not only does additional information 
influence valuation, the content of the additional information can have an 
equally strong impact. Further investigation around the content validity of 
vignettes would be recommended. In the meantime, care should be taken to 
provide objective information and vignettes should go through validity testing. 
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As described, adaptation information was removed from the study on the basis 
of the results of the pilot. Other work has shown similar results to the pilot 
study: that information about adaptation increased the utility values 
reported.(97) A future area of research could be how to incorporate adaptation 
into health state valuations. If an adjustment factor for adaptation were 
available, this could be incorporated into economic modelling (using patient 
level simulation) with, for example, a utility adjustment for length of time with 
the condition or length of time in a particular health state. 
The age of people completing the TTO may affect results. Dolan found that 
utility values elicited using the TTO for EQ-5D health states from those aged 60 
and over were lower than values from those aged 18-59.(98) AMD is a condition 
of older people, however, based on the recommendation to elicit preferences 
from a representative sample of the community (8) 
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5. Valuation of non-health benefits in vision 
This chapter investigate preferences for health and non-health attributes of 
AMD and its treatment and develops a weighting for health state utility values 
according to these preferences in order to address research aim 2: Are non-
health attributes important in AMD and how can they be incorporated into the 
cost-utility economic evaluation framework? 
 
5.1. Introduction 
To date, economic evaluations of treatments for AMD have focused on QALY 
maximisation for CUA. Previous chapters have investigated methods for 
measuring and valuing health state utilities for the calculation of QALYs for use 
in CUA. However, there are several aspects of AMD and its treatment that 
impact outside of health states that may contribute to public preferences on 
whether a new technology should be adopted. 
At the same time, decision makers have been looking at ways to account for a 
wider range of benefits than the QALY when assessing health technology. In the 
UK, the cancer drugs fund has operated since 2011, allowing a higher cost 
effectiveness threshold for drugs that meet certain end-of-life criteria.(99) 
In 2010 the UK Department of Health consulted on Value-based Pricing with the 
view that other attributes beyond the QALY.(100) It proposed that system 
should function as follows: 
 there would be a basic threshold, reflecting the benefits displaced 
elsewhere in the NHS when funds are allocated to new medicines; 
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 there would be higher thresholds for medicines that tackle diseases 
where there is greater “burden of illness”: the more the medicine is 
focused on diseases with unmet need or which are particularly severe, 
the higher the threshold; 
 there would be higher thresholds for medicines that can demonstrate 
greater therapeutic innovation and improvements compared with other 
products; 
 there would be higher thresholds for medicines that can demonstrate 
wider societal benefits. 
However, the budget constraint remains fixed, therefore introducing additional 
items on the benefit side requires a method to weight benefits currently 
considered by CUA (i.e. QALYs) to account for the opportunities forgone. 
DCEs are an increasingly popular method for eliciting preferences for health 
and health care.(43, 44) Respondents express preferences for hypothetical 
scenarios consisting of varying attributes drawn from all possible choice sets. 
Recently a DCE has been employed to derive distributional weights for 
QALYs.(101) Lancsar et al. demonstrated that a DCE could be used to elicit 
preferences for weighting QALYs due to other characteristics (age at onset, age 
at death if untreated and QoL if untreated). The study demonstrated that in 
certain circumstances, respondents chose to trade off some QALY gain for other 
characteristics. 
Meanwhile Linley and Hughes conducted a choice-based survey to investigate 
preferences for prioritising treatments by nine criteria including those in the 
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VBP consultation.(102) They found that respondents supported the criteria 
proposed by the VBP consultation (disease severity, unmet need, innovation 
and have wider societal benefits) but did not support a premium for end-of-life 
treatments, the prioritisation of treatments for children or disadvantaged 
populations, the special funding status for treatments of rare diseases, nor the 
Cancer Drugs Fund. 
Green and Gerrard investigated the social value of health technologies by 
presenting respondents with social value judgements (SVJs) in a DCE.(103) 
They included attributes for health improvement, value for money, severity of 
health, and availability of other treatments. 
Similar methods may be applied to investigate preferences for applying weights 
to health state utility values by aspects of the disease and its treatment in 
respect to AMD. The aim of this chapter was to investigate preferences for 
health and non-health attributes of AMD and its treatment and to develop a 
quantitative system by which these preferences could be applied to conduct an 
economic evaluation for a new treatment for AMD. 
 
5.2. Methods 
Attribute selection was guided by aspects of ranibiumab treatment, the current 
standard of care for AMD, which may be important to a health care decision 
maker. A number of other attributes were considered. Attributes that were 
excluded from the choice task were included in a final Likert scale survey 
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question to ascertain the importance of each attribute to inform future survey 
design. 
A common method for generating preference weights in DCEs is to include a 
cost attribute and calculate the marginal rate of substitution (MRS). In this 
experiment, it was decided that the attribute that would be used for weighting 
would be health gain and cost was not included as an attribute. 
 
5.2.1. Attributes and levels 
Four attributes were selected for the choice task. Three attributes had four 
levels and one attribute had two levels (Table 5.15). 
Health gain 
Health gain is the attribute that is currently maximised in CUA. Its inclusion 
allows health gain to be traded against other characteristics and distributional 
weights to be calculated using the Hicksian compensating variation. 
Four levels were identified: 5%, 10%, 15% and 20%. Levels offered a health 
gain as a percentage of health between 0% (dead) and 100% (perfect health) 
over 10 years. The scale was analogous to a health state utility scale where 0 is 
dead and 1 is perfect health. 
Severity 
Disease severity is an attribute that is often supported 
Four levels were identified: 20%, 40%, 60% and 80%. Levels described a 
starting level of health between 0% (dead) and 100% (perfect health). The scale 
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was analogous to a health state utility scale where 0 is dead and 1 is perfect 
health. 
Unmet need 
Ranibizumab treatment is considered relatively effective for wet AMD and is 
recommended for use in this population. However, there is currently no 
treatment available for patients with dry AMD. Preferences for a new product 
may differ between one that generates a health gain for patients with dry AMD 
compared with one that generates an equivalent health gain for patients with 
wet AMD. 
Two levels were identified: current treatment available and no current 
treatment available. 
Process 
The process of ranibizumab treatment may be considered relatively 
inconvenient for patients. Generally patients are required to attend the hospital 
for monthly injections. With the NHS pursuing policies that encourage improved 
process such as ‘care closer to home’,(104) it is important to test whether the 
public are willing to forgo some health gain by diverting resources to improved 
process. In terms of AMD, this could mean a treatment that may be 
administered at home, or one that is longer-acting, requiring a single hospital 
visit. 
Four levels were identified: monthly hospital injection, monthly home-based  
nurse-administered hospital injection, monthly home-based self-administered 
injection, one-off hospital injection 
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Attribute Levels 
Health gain over 10 
years 
+5% 
+10% 
+15% 
+20% 
Severity  20% 
40% 
60% 
80% 
Unmet need - Patients currently receive an existing adequate treatment, 
new treatment is an improvement 
- Patients currently receive basic NHS comfort care, but no 
adequate treatment currently exists 
Process - Monthly hospital appointment for injection 
- Monthly visit by nurse for injection 
- Monthly home-based self-administered injection 
- One-off hospital appointment for injection 
Table 5.15. Attributes and levels. 
 
5.2.2. DCE design 
The number of attributes and levels was guided by the following criteria: 
Amount of information 
Guidance from the literature is that a maximum of seven attributes can be 
considered by respondents at any time due to cognitive limits. It was 
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determined that the number of attributes should be lower than this due to the 
relative unfamiliarity of the task of prioritising health treatments. 
Length of survey 
A higher number of attributes and levels requires a greater number of choice 
tasks. A full factoral design would require 44 = 256 possible combinations. It 
was not necessary to constrain the design as the choice of attributes and levels 
meant there were no implausible scenarios. A main effects design was selected 
from an experimental plan catalogue and a foldover design selected to 
systematically vary the levels of the second choice. 
Based on information from piloting the survey in a convenience sample, the 
survey took approximately 15-20 minutes, which was considered a suitable 
length for online administration. 
A binary forced choice design was chosen which required the participant to 
choose option A or option B for each choice task. A ‘neither’ option was not 
included as it was considered realistic that a health care decision maker would 
fund one of the two options and not leave the budget unspent. Figure 5.12 is a 
screen shot of the survey showing one such choice. 
The choice of attributes and levels meant that there were no implausible 
combinations, so no combinations needed to be excluded from the design. 
The survey consisted of the following sections: 
- Introduction 
- Sociodemographic questions 
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- Introduction to choice tasks and practice task 
- Choice tasks (randomised) – 16 plus one choice with one set of attributes 
set to ‘best’ and one set to ‘worst’ to test understanding. 
- Likert scale to rate importance of other attributes 
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*The full list of choice tasks is provided in Appendix B. 
 
Sample 
800 respondents were recruited via an online survey panel. Criteria were set 
that the respondents must be from the UK and be at least 18 years of age in 
order to represent UK general public preferences. As described in the next 
section, respondents were stratified into four groups, receiving the same choice 
tasks, with different perspectives. 
Figure 5.12. Screenshot of choice task. 
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5.2.3. Impact of perspective and framing 
 
 Ex ante Ex post 
Personal What value do you attach to 
treatment being available 
should you need it? 
What value do you attach to your 
own treatment? 
Social What value do you attach to 
treatment being available to 
others should they need it? 
What value do you attach to the 
treatment of others? 
Socially 
inclusive 
personal 
What value do you attach to 
treatment being available to a 
group of people amongst whom 
you might find yourself? 
What value do you attach to the 
treatment of yourself and others? 
Table 5.16. Six perspectives for eliciting preferences.  
*Adapted from Dolan et al.(47) 
 
There are a number of perspectives that can be used to elicit preferences (Table 
5.16).(47) In health state valuation, it is common for preferences to be elicited 
for oneself from behind a veil of ignorance (personal ex ante). For example the 
TTO asks a respondent to imagine that they are in a given health state and 
elicits how much time they would trade for perfect health. 
The use of DCEs to derive distributional weights is relatively novel. However, 
approaches to date have asked respondents to prioritise treatments for groups 
of patients (others), social ex ante. 
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The perspective of the choice may have an impact on preferences for resource 
allocation. For example, risk aversion or the importance of process relative to 
health gain may vary when thinking of oneself compared with choosing for 
others. Three perspectives were chosen to reflect choosing for oneself, choosing 
for others and an intermediate perspective of choosing for others like oneself. 
These perspectives also reflected those being investigated in the re-valuation of 
the EQ-5D value-set. Additionally a labelled version of the survey was designed 
to investigate whether additional information impacted on preferences. 
Four surveys were designed with identical choice tasks, but taking the following 
different perspectives. Each survey was completed by 200 adult members of the 
UK general public recruited via an online survey panel. 
Others 
Respondents were asked to choose to fund one of two new treatments offered 
for two different groups of patients imagining that they are the health care 
decision maker. 
Someone like you 
Respondents were asked to choose to fund one of two new treatments offered 
for two different groups of patients imagining that someone like themselves is 
in each of the groups. 
You 
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Respondents were asked to choose to fund one of two new treatments offered 
for two different groups of patients imagining that they have an equal chance of 
being in either of the two groups. 
Labelled others 
A labelled version of the survey was identical to the ‘others’ perspective, but 
respondents were informed the treatment choices were for AMD and read a 
short description of the condition before beginning the choice tasks. The AMD 
label was taken from the NHS Choices website, which is designed to help 
patients understand diseases and treatments.(56) In the choice tasks, the no 
adequate treatment option was labelled as ‘dry AMD’ and the adequate 
treatment option was labelled as ‘wet AMD’ to reflect the current situation in 
clinical practice where wet AMD has a treatment (ranibizumab injections) and 
dry AMD has no treatment, only rehabilitation to help patients to adapt to the 
condition. 
Box 5.1. AMD label. 
Age-related macular degeneration is a painless eye condition that leads to the gradual 
loss of central vision. Central vision is used to see what is directly in front of you, during 
activities such as reading or watching television for example. The central vision 
becomes increasingly blurred leading to symptoms including 
- Difficulty reading printed or written text (because it appears blurry) 
- Colours appear less vibrant 
- Difficulty recognising people’s faces 
There are two main types of AMD: 
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Dry AMD develops when the cells of the macula become damaged due to lack of 
nutrients and a build-up of waste products called drusens. 
Wet AMD develops when abnormal blood vessels from underneath the macula and 
damage its cells (doctors sometimes refer to wet AMD as neovascular AMD). 
There is currently an effective injection for wet AMD. For dry AMD, there is currently 
no treatment and patients receive basic NHS care such as training to use low vision aids 
like magnifiers. AMD usually affects both eyes but the seed in which it progresses can 
vary from eye to eye. 
 
5.2.4. Statistical methodology 
Model 
Discrete choice responses are modelled within a random utility framework. For 
QALY maximisation to hold, utility would be a function of health gain alone. If 
other characteristics are important, utility will be a function of health gain and 
other characteristics (Equation 5.1). 
 
V = f (HG,S,UN,Phomenurse,Phomeself ,Ponehospital ) 
Equation 5.1. Utility function. 
where Health gain (HG), Severity (S), Unmet need (UN), Process (P) 
 
Process attributes were coded as dummy variables. The reference was chosen 
as monthly hospital injections. 
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The limitations of an additive function is that it assumes that other attributes 
have an effect on utility where health gain is zero. Assuming a multiplicative 
model instead, a log-linear model is generated (Equation 5.2). 
 
log(V)= b1 log(HG)+b2 log(S)+b3 log(UN)+b4 log(Phomenurse)+b5 log(Phomeself )+b6 log(Ponehospital ) 
Equation 5.2. Log-linear model of utility function. 
 
A conditional logit model can be estimated (Equation 5.3). 
 
D log(V )= b1(D log(HG))+b2(D log(S))+b3(D log(UN))+b4(D log(Phomenurse))+b5(D log(Phomeself ))+b6(D log(Ponehospital )) 
Equation 5.3. Conditional logit model. 
 
The model allows for the fact that each individual responds to several choice 
questions. The clogit command was used in STATA in order to calculate 
coefficients for individual attributes. 
Utility weights for these attributes were derived using the compensating 
variation method. As per Lancsar et al.,(101) the marginal utility of a QALY was 
used to value the change in expected utility arising from a move from the 
reference to alternative case in order to derive CV.(Equation 5.4) Given the 
marginal utility of a QALY represents the slope of the utility function with 
respect to QALYs and, due to the non-linear functional form of the choice model 
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the slope of the utility function will be smaller for larger QALY gains. It was 
decided that a gain of one QALY would be used to calculate the marginal utility 
of a QALY used in the CV equation in common with the range of QALY gains 
often seen in HTA.(4) 
 
Utility weights 
CV =
1
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Equation 5.4. Compensating variation. 
 
Weight =
1-CV
Utilitybase
 
Equation 5.5. Utility weights. 
 
Weights for individual attributes 
In order to calculate utility weights for each attribute, a reference case was 
chosen against which the alternative scenarios would be compared: 
 Health gain = 10% over 10 years 
 Severity = 60% 
 Unmet need = adequate treatment available 
 Process = monthly hospital 
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5.3. Results 
A total of 813 responses were received. 
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Characteristic Value 
Age 18 to 24 3% 
25 to 34 12% 
35 to 44 16% 
45 to 54 25% 
55 to 64 26% 
65 to 74 15% 
75 or older 3% 
Gender Female 53% 
Male 47% 
Employment status Unemployed, retired, student 43% 
Manual worker (with no qualifications) 6% 
Manual worker (with industry 
qualifications) 
8% 
Supervisor, clerical; junior managerial, 
administrative or professional 
23% 
Intermediate managerial, administrative 
or professional 
14% 
Senior manager or professional 6% 
Health status (where 0 = dead and 100 = perfect), Mean (SD) 71 (24) 
Disability Yes 26% 
No 73% 
Prefer not to say 1% 
Table 5.17. Respondent characteristics. 
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Figure 5.13. Bar chart of responses to ‘long list’ of possible attributes. 
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In order to validate the choice of attributes, a longer list was presented to 
respondents who were asked to rate the importance of each. The most 
important attributes (measured by the number of ratings of very important and 
extremely important) were current level of health, terminal illness, health 
improvement from treatment, location of care and other adequate treatment 
being available. Unimportant attributes were gender, socioeconomic group and 
ethnic group. (Figure 5.13) 
The results confirmed the selection of attributes for the choice task. Only 
terminal illness was not included from those ranked most important. Since the 
study focused on a disease and treatment that affects quality of life and not 
length of life, this attribute could not be practically included. 
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Table 5.18. Coefficients derived from conditional logit models. 
* significant at p<0.1 **significant at p<0.05 
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The coefficients derived from conditional logit models of the four surveys are 
described in Table 5.18. Across all scenarios, the coefficients for health gain 
were positive and were significant at p<0.05, meaning that respondents 
preferred treatments that provided a greater health gain. 
Across all scenarios the coefficients for severity were negative and were 
significant at p<0.05, meaning that respondents preferred treatments that were 
for patients with a lower starting level of health. 
Unmet need was only significant for respondents answering the choices about 
themselves, with a negative coefficient meaning that respondents preferred 
treatments that addressed a disease without an adequate treatment currently 
available. This attribute was not significant for respondents answering the 
choices about others. 
Process of care was significant across all scenarios except someone like you 
(where only a monthly home nurse visit was significant). All scenarios had 
positive coefficients, indicating that respondents preferred home treatments or 
less frequent hospital-based treatments over monthly hospital treatments. 
In the ‘you’ scenario, respondents answering about themselves appeared to 
have a less strong preference for health gain, instead severity and unmet need 
had larger coefficients compared with the three other scenarios where 
respondents were answering about others. When prioritising treatments for 
oneself, attributes other than health gain become relatively more important. 
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Table 5.19. Weights for individual attributes. 
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Reference case: HG=10% (1 QALY over 10 years), S=60%, UN=no adequate treatment available, 
P=monthly hospital. CV=compensating variation to move from reference case. 
 
In the ‘dominant’ choice task included to test for the rationality of responses 
(Table 5.20), 73.0% of respondents chose the dominant option. This ranged 
from 70.1% in the ‘you’ sample to 77.3% in the ‘label’ sample. 
 
Attribute Choice A Choice B 
Health gain +20% +5% 
Severity 20% 80% 
Unmet need No adequate treatment 
currently available 
Adequate treatment 
currently available 
Process One-off hospital Monthly hospital 
Table 5.20. 'Dominant choice'. 
 
5.4. Conclusion 
This study derived distributional weights for QALYs, allowing the external 
weighting of health gain by other characteristics. This allows the preferences for 
other characteristics to be incorporated into the cost-per-QALY economic 
evaluation framework. 
Respondents were willing to forego health gain for other attributes. This 
indicates that the UK public may wish that QALYs gains be modulated by 
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severity of disease, process of care (and to a lesser extent) unmet need when a 
new treatment is evaluated for use in the health care system. 
Preference elicitation is influenced by the perspective of the DCE task. It 
appears that preferences are affected by a change in perspective, but remain 
stable to framing. There is evidence that preferences for treating self are 
different to treating others. 
This study does not itself provide evidence on the most appropriate perspective. 
The choice of perspective is a normative decision. When weighting QALYs, is it 
most appropriate for public preferences to reflect those of the decision-maker 
(someone else), or to be consistent with utilities (you)? 
This study was limited in the attributes under consideration. Future work is 
needed to investigate additional attributes. The rating task undertaken by 
respondents on a longer list of attributes gives some guidance on what may be 
included in future choice tasks. 
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6. Definition of health states in vision 
This chapter investigates the association between measures of visual function 
and utility in AMD health states. A CUA model is developed to test the impact on 
cost effectiveness of using different individual measures of visual function and a 
mapping algorithm is developed from visual function to utility in order to 
address research aim 3: How is visual function associated with utility in AMD and 
how can the association be applied to economic evaluation? 
 
6.1. Association between VA and utility 
There is evidence that VA alone may not fully account for changes in health 
status in visual disorders. Indeed, CS has been shown to impact on quality of life 
in AMD, not only VA. In an observational study to determine this relationship, 
CS remained a statistically significant predictor of all outcome measures even 
when VA was included.(59) 
VA measures the eye’s ability to resolve fine detail, whereas, CS measures ability 
to see low contrast patterns and VF allows peripheral vision. Although good VA 
is necessary for activities such as reading, it is only weakly associated with 
ability to discriminate between visual targets or performance of tasks requiring 
distance judgment. 
Therefore, both VA and CS can be expected to impact on a patient’s quality of life 
and consequently that utility values based on VA alone may underestimate 
quality of life. 
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Further evidence of the weak association between VA and utility is derived from 
analysis of the dataset used to test the performance of EQ-5D, SF-6D, TTO and 
VAS (Chapter 3). 
The relationship between VA in the better-seeing eye and the four utility 
measures are shown in Figure 6.14. There was no association between VA and 
any utility measure (Pearson correlation; all R < 0.04; p > 0.2). 
This raises concerns that treatment decisions based on this outcome measure 
may reflect neither public nor patient preferences on how health care resources 
should be allocated. This is believed to be the first comparison of VA from 
hospital records and preferences. The finding is especially concerning given that 
most CUA of AMD interventions have used Markov models based on the 
association between VA and health state utility.(62) However, it is also 
unsurprising given that most AMD patients are likely to have multiple 
comorbidities unrelated to vision, which may also have an impact on the utility. 
The low explanatory power of VA has been identified in other studies and other 
measures of vision such as CS may be better associated with health state 
utility.(59) Given that this data did not measure VA, but recorded it from 
hospital notes, another explanation for the weak agreement could be that the 
hospital notes may not represent accurate or up-to-date measures of the 
patient’s vision. 
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Figure 6.14. Association between VA and utility. Data from 58 patients described in Chapter 3. 
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6.2. VA vs. CS in health economic models 
Previous health economic models in treatments for AMD, including those used 
to develop the UK NICE’s guidelines on ranibizumab and pegaptanib for AMD, 
have relied on the association between VA and health state utility to construct 
Markov models.(2) Yet there is evidence that anti-VEGF therapy is effective in 
reducing the deterioration in CS, another measure of visual function.  
A cost-effectiveness model based on CS outcomes may offer advantages over 
previous modelling techniques. Firstly, no single visual function outcome 
captures HRQoL in AMD and interventions may have a differential impact on 
each outcome. CS has an independent impact on health state utility and has 
been shown to be more closely associated with HRQoL than VA.(59) CS was 
found to remain a statistically significant predictor of utility even when VA was 
included in a regression model. VA measures the eye’s ability to resolve fine 
detail at high contrast, while CS measures the ability to perceive differences 
between light and dark.(105)  
Secondly, utility values for CS have been reported for binocular vision, so a 
model based on this outcome takes account of visual function in both eyes. 
Models based on VA outcomes alone have considered only visual function in the 
better seeing eye, while the impact of the worse seeing eye on health state 
utility values is uncertain.(106) In clinical practice, the eye with the disease will 
be treated, whether this is the better or worse seeing eye, therefore, taking 
account of vision in both eyes more closely reflects clinical practice. 
Only one previous model has investigated cost-effectiveness using CS. Bansback 
et al. investigated the cost-effectiveness of photodynamic therapy (PDT) with 
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verteporfin for AMD and estimated an incremental cost-effectiveness of 
approximately GBP20,996 over 10 years compared to best supportive care.(60) 
   
From the previous model, it was not possible to compare the implications of 
using CS or VA on the cost-effectiveness of treatments for AMD since there was 
no directly comparable VA model. Furthermore, in recent years, PDT has been 
replaced by anti-VEGF therapy as standard clinical practice to treat AMD, so 
there is no estimate of the cost-effectiveness of current clinical practice using CS. 
Economic evaluations of treatments for AMD have concluded that the two anti-
VEGF therapies used within the NHS, approved ranibizumab and off-label 
bevacizumab (Avastin®, Roche Holdings AG, Switzerland), are cost-effective at 
commonly applied thresholds when compared with photodynamic therapy 
(PDT) with verteporfin.(2, 62) A recent head-to-head comparison found no 
significant difference between the two drugs in terms of effectiveness.(63) 
This model assesses the cost-effectiveness of anti-VEGF therapy using CS for the 
first time and investigates the impact on cost-effectiveness of basing a model on 
CS compared with VA. 
The choice of using VA or CS in the model is a case of structural uncertainty, the 
impact of which can only be tested by redesign of the model.(107)In this 
chapter two Markov models are developed based on the Avastin (bevacizumab) 
for choroidal neovascular age-related macular degeneration (ABC) trial, which 
assessed VA and CS outcomes in AMD patients. Bevacizumab was compared 
with standard NHS treatment at the time of the trial, which was a mixture of 
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PDT with verteporfin (Visudyne®, Novartis AG, Switzerland), pegaptanib 
(Macugen®, Pfizer, USA), an alternative anti-VEGF and no treatment (sham 
injection) depending on the clinical diagnosis. The trial demonstrated that 
bevacizumab was an effective treatment in terms of both outcomes.(108, 109) 
 
6.2.1. Methods 
State transition Markov models were constructed to simulate the progression of 
the disease in terms of VA and CS. The VA model had 4 states of VA in the better-
seeing eye and a death state. The CS model had 4 states of binocular CS and a 
death state. (Figure 6.15) States were chosen that represented clinically 
relevant levels of visual function and had associated utility values. 
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A 
B  
 
Figure 6.15. Markov models. A. Visual acuity states (better seeing eye logMAR). B Contrast 
sensitivity states (binocular log units) 
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In the models, patients were allowed to move forwards to a better health state, 
move backwards to a worse health state, remain in their current health state or 
die at each model cycle. Death was an absorbing state, meaning that patients 
could not leave the state. 
 
 Bevacizumab (n=65) Comparator (n=66) 
Gender  
   - Male 26 25 
   - Female 39 41 
Mean age (years) 79 81 
Mean ETDRS VA in study 
eye (logMAR) 
0.68 0.64 
Mean binocular CS (log 
units) 
1.26 1.22 
Table 6.21. Baseline summary of patient demographics in the ABC trial. 
 
Transition probabilities were calculated from patient level data on VA and CS 
from the ABC trial (n=131, Table 6.21). Better-seeing eye VA transition rates 
were approximated from the study eye. As CS measurement was monocular, 
binocular CS transition rates were estimated using a published algorithm, which 
found that binocular CS could be calculated as the square root of the sum of the 
square of each eye.(110) Age-specific mortality rates were taken from the Office 
for National Statistics rates for England and Wales for 2009.(111) The rates 
were adjusted to take account of the sex of the cohort using the ratio of 
participants in the ABC trial. (B. 
Table 6.22) 
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A.  
VA (better seeing eye 
logMAR) 
1.31 - 2.00 0.61 - 1.30 0.31 - 0.60 ≤0.30 
To bevacizumab     
1.31 - 2.00 0.62 0.03 0.00 0.01 
0.61 - 1.30 0.33 0.80 0.10 0.00 
0.31 - 0.60 0.00 0.16 0.72 0.24 
≤0.30 0.05 0.01 0.17 0.76 
     
To comparator     
1.31 - 2.00 0.85 0.06 0.03 0.00 
0.61 - 1.30 0.11 0.84 0.22 0.05 
0.31 - 0.60 0.04 0.10 0.69 0.63 
≤0.30 0.00 0.00 0.07 0.32 
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B. 
Table 6.22. Transition probabilities between Markov states for bevacizumab and comparator. A. 
Visual acuity (VA). B. Contrast sensitivity (CS). 
 
The trial measured VA every six weeks and CS every 12 weeks for 54 weeks. 
The cycle length was 6 weeks for the VA model and 12 weeks for the CS model, 
reflecting the ABC trial protocol. 
SF-6D utility values reported by Espallargues et al. were applied to the health 
states in the model. 209 patients with unilateral or bilateral AMD at a hospital in 
Sheffield, UK were asked a series of preference-based questionnaires and the 
derived utility values were associated with their visual function. The SF-6D 
showed greater sensitivity than the EQ-5D, but less sensitivity than the HUI-3 to 
changes in vision. The SF-6D derived utilities were chosen over the HUI-3 since 
CS (binocular log units) <0.30 0.30 - 0.90 0.91 - 1.30 >1.30 
To bevacizumab     
<0.30 1.00 0.06 0.00 0.00 
0.30 - 0.90 0.00 0.44 0.04 0.00 
0.91 - 1.30 0.00 0.50 0.77 0.11 
>1.30 0.00 0.00 0.19 0.89 
     
To comparator     
<0.30 0.00 0.03 0.00 0.00 
0.30 - 0.90 0.00 0.67 0.10 0.01 
0.91 - 1.30 1.00 0.31 0.69 0.29 
>1.30 0.00 0.00 0.20 0.70 
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the HUI-3 showed little agreement with other measures and gave extremely low 
utility scores compared to other measures. The HUI-3 reported a utility of just 
0.10 for the worst VA state, compared with 0.63, 0.63 and 0.47 for the EQ-5D, 
SF-6D and TTO respectively. TTO utilities were applied as sensitivity analysis. 
The utilities values grouped by levels of VA and CS were applied to the model 
health states.(58)  (Table 6.23) 
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A. 
B. 
CS (binocular, log units) Utility, mean (95% CI) 
<0.30 0.65 (0.11) 
0.30 to 0.90 0.64 (0.14) 
0.91 to 1.30 0.68 (0.14) 
>1.30 0.73 (0.16) 
Table 6.23. Utility values assigned to health states. A. Visual acuity (VA). B. Contrast sensitivity (CS). 
*Utilities calculated from SF-6D by Espallargues et al. (58) 
 
  
VA (better seeing eye, logMAR) Utility, mean (95% CI) 
1.31 to 2.00 0.65 (0.11) 
0.61 to 1.30 0.66 (0.14) 
0.31 to 0.60 0.67 (0.14) 
≤0.30 0.70 (0.18) 
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Item Unit cost Source 
Avastin £242.66 BNF 
Macugen £514.00 BNF 
First PDT with verporfin £1,181.00 Bansback et al. 
Subsequent PDT with verporfin £1,113.00 Bansback et al. 
Ophthalmic antibiotic £2.17 BNF 
Anaesthetic £0.45 BNF 
Dilating drops £0.45 BNF 
Initial consultation £179.63 Patel et al. 
Subsequent consultation £49.98 Patel et al. 
Eye examination £51.00 Patel et al. 
Optical coherence tomography £44.00 Patel et al. 
Table 6.24. Unit costs. 
*BNF= British National Formulary.(60, 112) 
 
Resource use was estimated from the ABC trial protocol and presented in 
British Pounds. (Table 6.24) Treatment rates were calculated from the trial to 
reflect that patients were not treated at every time point. If treated, costs were 
incurred from the drug, the examination and the consultation. Otherwise, only 
costs associated with the examination and consultation were incurred. A higher 
cost was applied to the first consultation to reflect a more extensive first visit. 
(Table 6.25) 
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A. 
  
VA (6-week cycle) First cycle Subsequent cycle 
Bevacizumab   
Drug £208 £208 
Examination £95 £95 
Consultation £180 £50 
Total £483 £353 
   
Comparator   
Drug £374 £367 
Examination £95 £95 
Consultation £180 £50 
Total £649 £512 
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B. 
 
Unit costs for drugs were obtained from the British National Formulary (BNF) 
and adjusted for the volumes used in the ABC trial. Consultation and 
examination costs were obtained from other published AMD models.(60, 112) 
The perspective of the model was the UK NHS and personal social services as 
recommended in the NICE Guide to the Methods of Technology Appraisal 
reference case.(2) Each model was run for 5 years, which represented an 
extension of the 54-week trial follow-up and captures the long-term costs and 
effects of the treatments. Since there is no evidence on the long-term outcomes 
of anti-VEGF therapy on either VA or CS, it was assumed that transition rates 
CS (12-week cycle) First cycle Subsequent cycle 
Bevacizumab   
Drug £416 £416 
Examination £191 £191 
Consultation £230 £100 
Total £836 £707 
   
Comparator   
Drug £747 £733 
Examination £191 £191 
Consultation £230 £100 
Total £1,168 £1,024 
Table 6.25. Costs per cycle. A. Visual acuity (VA). B. Contrast sensitivity (CS). 
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estimated from the 54-week trial were maintained to 5 years. A discount rate of 
3.5% for costs and QALYs was applied as recommended by UK HM Treasury.(9) 
The model compared bevacizumab (1.25mg in 0.05ml per injection) with a 
comparator of mixed standard care in the UK in 2009 (16 patients received PDT, 
38 patients received pegaptanib, 12 patients received sham injection) as used in 
the ABC trial. 
Appropriate probability functions were fitted to model parameters to 
incorporate uncertainty. Probabalistic sensitivity analysis was performed using 
Monte Carlo simulation to randomly sample each parameter.(113) Utilities 
were characterised by a beta distribution, costs by a gamma distribution and 
transition probabilities by a dirichlet distribution. A cost-effectiveness 
acceptability curve (CEAC) was constructed to represent the probability of the 
treatment proving cost-effective at a given value of health effect.(114) One-way 
sensitivity analysis was employed to test structural uncertainty within the 
model. 
 
6.2.2. Results 
The models indicate that bevacizumab is less costly and more effective than the 
comparator treatment over 5 years using either VA or CS outcomes 
(bevacizumab dominates the comparator). 
A higher incremental QALY gain is obtained from the CS model compared with 
the VA model. The central estimates of the probabilistic sensitivity analysis are 
0.076 in the CS model and 0.061 in the VA model, which indicates that 
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bevacizumab is 25% more effective using CS outcomes than the VA outcomes. 
(Table 6.26) This difference was statistically significant (P<0.05) when 10,000 
Monte Carlo simulations of the model were assessed using an unpaired t-test. 
 
VA Comparator Bevacizumab Incremental 
Cost £21,258 £14,714 -£6,545 
QALYs 3.028 3.089 0.061 
ICER Bevacizumab dominates 
 
CS Comparator Bevacizumab Incremental 
Cost £20,931 £14,490 -£6,441 
QALYs 3.114 3.190 0.076 
ICER Bevacizumab dominates 
Table 6.26. Central cost-effectiveness results: average of Monte Carlo analysis 
*5-year time horizon, 3.5% discount rate for costs and QALYs. 
 
The results remain robust when parameters were varied in sensitivity analysis. 
Bevacizumab dominates the comparator in all model assumptions varied in 
one-way sensitivity analysis (Table 6.27). The CS model generates a higher 
incremental QALY gain than the VA model in all scenarios. The model is most 
sensitive to the choice of utility set.  
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Table 6.27. One-way sensitivity analysis. A. Visual acuity (VA). B. Contrast sensitivity (CS). 
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Bevacizumab remains cost-effective when probabilistic sensitivity analysis is 
applied to utilities, costs and transition probabilities. Figure 6.16 shows the 
probabilistic sensitivity analysis on a cost-effectiveness plane. 
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Figure 6.16. Cost-effectiveness plane of incremental costs + QALYs for bevacizumab vs. comparator. 
A. Visual acuity 
B. Contrast sensitivity 
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The CEAC highlights that for the same cost as the comparator, bevacizumab has 
a probability of being cost-effective of more than 60% when assessed using VA 
and 65% when assessed using CS (Figure 6.17). At most costs, there is a higher 
probability of bevacizumab being cost-effective in the CS model than in the VA 
model. 
 
 
Figure 6.17. Cost-effectiveness acceptability curve. VA = visual acuity, CS = contrast sensitivity. 
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6.2.3. Conclusion 
The choice of outcome represents a major source of structural uncertainty when 
constructing models to assess the cost-effectiveness of treatments for AMD and 
has been shown to have a large impact on cost-effectiveness estimates. 
Bevacizumab appears more cost-effective when assessed using CS outcomes 
rather than VA outcomes. In this trial, as bevacizumab dominates the 
comparator, the decision on the use of bevacizumab in AMD would not be 
altered by the choice of outcome used in the model. 
The difference in incremental QALY gain between the CS and VA models when 
assessing the cost-effectiveness of anti-VEGF therapy is potentially significant in 
health care decision-making, particularly in decisions close to the cost-
effectiveness threshold. The uncertainty associated with the choice of clinical 
variable to associate with utility cannot be assigned a distribution and tested 
using probabilistic sensitivity analysis as is frequently done for costs, utilities 
and transition rates. 
Another anti-VEGF therapy, ranibizumab, is currently recommended for 
treatment of AMD patients within the NHS.(73) It has been shown to be equally 
effective to bevacizumab, but is more costly.(63, 115) It can be expected that a 
higher QALY gain would be accumulated and a lower ICER would be achieved in 
a model based on CS rather than previously used VA, although this cannot be 
directly concluded from the current study due to a different intervention and 
comparator. 
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Traditionally, a CEAC such as that shown in Figure 6.17 would only show 
positive values of health effects. However, the negative value of health effect is 
shown to allow inferences to be made about how the two outcomes may impact 
on the cost-effectiveness of a more costly drug. The CEAC demonstrates that for 
a given value of health effect, the CS model predicts bevacizumab to be more 
likely to be considered cost-effective. 
There are two potential reasons for the different QALY estimates from the two 
models. Firstly the closer association between CS and HRQoL may mean that the 
CS model is more accurately representing the utility gain of the treatment than 
the VA model. Alternatively, the intervention may have a differential effect on 
VA and CS and anti-VEGF therapy may improve CS more than VA in terms of 
relative utility. 
There are a number of limitations with this study. The comparator treatment (a 
mixture of pegaptanib, PDT and no treatment) as used in the ABC trial is no 
longer standard NHS practice since the approval of ranibizumab. This limits 
interpretation of the absolute ICERs. Indeed, the absolute size of the 
incremental QALY gain in both models is small because the comparator in this 
trial was an active intervention. A comparison of bevacizumab with 
ranibizumab based on CS outcomes would be a valuable area for future research. 
Furthermore, another anti-VEGF therapy, aflibercept (®Bayer) is approved for 
the treatment of AMD in the USA and has been shown to be equally effective 
compared with bevacizumab and ranibizumab.(116) NICE is currently 
reviewing the use of aflibercept for AMD in the UK. 
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Both VA and CS have limitations when measuring very poor vision. Both 
measures rely on patients reading letters on a chart, so when patients cannot 
read the first letter, patients are assumed to have the most severe health state in 
the model. 
Transition rates were based on trial data and allowed patients’ vision to worsen, 
remain the same or improve at each cycle. Anti-VEGF therapy is generally 
believed to maintain or reduce deterioration in vision rather than improve it. 
However, the nature of VA and CS as performance measures means there may 
be variation in the exact scores achieved by patients on each visit. 
These models do not include adverse events. The number of adverse events in 
the ABC trial was very low. Given the incidence in the two models would be the 
same, adverse events should not impact on the difference between VA and CS 
identified. 
Generally, these results highlight that the choice of clinical outcome on which a 
model is based can have a large impact on the cost-effectiveness estimates of 
the model. Attention should be paid to the association between clinical disease 
states and HRQoL when developing health economic models. The clinical 
outcome that is best associated with HRQoL in the condition should be used 
where practical. If there is uncertainty over the most suitable clinical outcome 
for defining model states, the alternatives could be presented in one-way 
sensitivity analysis.  
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6.3. Visual function algorithm 
Given 
 the weak association with VA 
 the large impact on cost effectiveness estimates of using different aspects 
of visual function in economic models 
It appears desirable to investigate individual and combined mapping algorithms 
from visual function to utility. 
 
6.3.1. Methods 
Multiple OLS and tobit regression models were developed to associate 
individual and combined measures of visual function (and sociodemographic 
covariates) with utility. 
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Dependent 
variable 
Independent variables Model types Performance 
EQ-5D index 
(utility) 
-VA 
- CS 
-Microperimetry 
-Linear 
ordinary least 
squares 
-Tobit 
(outputs 
censored at 1) 
Goodness of fit: 
-Statistical 
significance, sign and 
size of coefficients 
- R-squared 
Predictive ability: 
-Root-mean squared 
error (RMSE) 
-Observed vs. 
predicted scores 
Table 6.28. Approach to mapping. 
*Adapted from Longworth et al.(117) 
 
Sample 
It was intended that a mapping algorithm would be developed based on 200 
patients with AMD from the baseline data of the Eccentric Fixation From 
Enhanced Clinical Training (EFFECT) randomised control trial. The sample size 
was estimated based on Espallargues et al. which elicited utility values for levels 
of VA and CS had a sample size of 207.(58) 
EFFECT trial recruitment began in July 2011 with a projected recruitment rate 
of 3 patients per week. Consequently the full baseline sample was projected to 
be available in November 2012. 
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Due to a slower than anticipated rate of recruitment, the full sample was 
unavailable. Data was extracted in July 2013. Baseline data from 81 patients 
were available for development of the mapping algorithm. (Table 6.29)  
Dependent variable 
The dependent variable was utility derived from the EQ-5D. The 5-level EQ-5D 
was administered to patients. Utility values were calculated using the EuroQoL 
5L interim value-set for UK public preferences. 
The TTO (patient utility) was also planned to be analysed as sensitivity analysis. 
Due to the number of refusals and non-traders for the TTO, data was only 
available for 19 subjects. Due to the very small sample, it was decided to 
proceed only with the EQ-5D. 
Independent variables  
VA was measured using an ETDRS letter chart and recorded in logMAR. Left eye, 
right eye and binocular VA was measured. The better eye was identified based 
on the better VA. 
CS was measured using a MARS chart, and recorded in log units. Left eye and 
right eye CS was measured. Binocular CS was calculated using from the vector 
sum of the study and fellow eyes. 
Retinal microperimetry of the left and right eyes was measured using a Nidek 
MP-1 microperimeter. Microperimetry was used to approximate the size of the 
scotoma. A data file of containing each point presented and its location was 
extracted for each eye of each patient and the proportion of points seen within 
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the potential visual field was calculated. (see Appendix B for details of how 
microperimetry data was used to approximate the size of the scotoma). 
Sociodemographic variables were age, gender, diagnosis (wet or dry AMD), and 
comorbidities. Comorbidities were included as the sum of conditions mentioned 
by the patient in an open-ended question phrased as “Please list any other 
conditions that you have today”. 
Subjects with one or more missing variables were excluded from the model. 
Analysis was conducted using Stata 12 (StataCorp). 
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Variable Value 
N 81 
Mean age, years (SD) 80.8 (11.2) 
Female, % 61.7 
Mean ETDRS better eye VA, logMAR (SD) 0.64 (0.24) 
Mean binocular CS, log units (SD) 1.37 (0.34) 
Wet AMD, % 62.5 
Mean utility, EQ-5D-5L UK interim value-set 
(SD) 
0.66 (0.21) 
Table 6.29. Sample characteristics. 
 
6.3.2. Results 
Correlation coefficients were calculated for variables. Pairwise deletion was 
used for missing data i.e. data points are deleted from the calculation of the 
correlation if one or both of the data points in that pair was missing. 
Correlations were in the expected direction. As logMAR acuity increased, or 
vision worsened, generally contrast decreased (worsened) and % points seen in 
microperimetry decreased (worsened). However, only the correlation between 
better eye and binocular CS and % points seen in microperimetry were 
significant at p<0.05. 
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Table 6.30. Correlation coefficients. 
*significant at p<0.1  **significant at p<0.05 
 
 172 
Models were developed for visual function variables alone (short, Table 6.31) 
and for visual function variables plus sociodemographic variables (long, Table 
6.32). Comorbidities reduced the explanatory power of the model and were 
therefore excluded. 
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Variable OLS Tobit 
 Coef. SE P>t Coef. SE P>t 
Better eye VA -0.081 0.105 0.447 -0.095 0.105 0.371 
Binocular CS 0.069 0.080 0.392 0.070 0.080 0.384 
% points seen 
microperimetry 
-0.053 0.148 0.721 -0.068 0.149 0.651 
Constant 0.646** 0.141 0.000 0.667** 0.142 0.000 
       
Prob > F 0.695   0.643   
R-squared 0.023   -0.080   
Root MSE 0.196   -   
Obs. 67   67[1]   
Table 6.31. Short models of the association between visual function and utility. 
[1] 2 right-censored observations at utility ≥1. *significant at p<0.1. 
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Variable OLS Tobit 
 Coef. SE P>t Coef. SE P>t 
Better eye VA -0.177* 0.099 0.078 -0.195** 0.096 0.047 
Binocular CS 0.052 0.078 0.502 0.051 0.075 0.495 
% points seen 
microperimetry 
0.009 0.140 0.950 -0.004 0.137 0.978 
Age -0.003 0.002 0.117 -0.003* 0.002 0.095 
Gender (female) -0.059 0.047 0.215 -0.060 0.045 0.190 
Diagnosis (wet) 0.185** 0.047 0.000 0.191** 0.046 0.000 
Constant 0.855** 0.213 0.000 0.884** 0.207 0.000 
       
Prob > F 0.004   0.002   
R-squared 0.274   -1.140   
Root MSE 0.176   -   
Obs. 64   64[1]   
Table 6.32. Full models of the association between visual function and utility. 
[1] 2 right-censored observations at utility ≥1. *significant at p<0.1. **significant at p<0.05 
 
An algorithm associating visual function and utility was generated from the 
Tobit full model using VA in the better eye, age and diagnosis. The variables to 
be included in the algorithm were selected based on a significance level of p < 
0.1. This algorithm may be considered exploratory due to using a smaller 
sample than anticipated. 
Equation: 
V = (0.884) – (0.195xVA_better) – (0.003xAge) + (0.191xWet)   
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The performance of the model was assessed by comparing predicted values 
from the algorithm with patient’s actual EQ-5D utility scores. Algorithm 
predictions were based on patient’s own acuity, age and diagnosis. The 
algorithm followed the trend of the actual data, but diverged at extreme upper 
and lower values. 
 
 
Figure 6.18. Actual vs. predicted utility scores in algorithm sample. 
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The independent dataset chosen was the 58 AMD patients who answered a 
range of utility instruments as described in Chapter 3. The characteristics of 
these patients are summarised in Section 3.1.3. To summarise, mean age was 
83.8 (SD = 6.5) years, Seventy nine percent of patients (46) had a diagnosis of 
wet AMD. Mean best-corrected VA in the better seeing eye was 0.65 (SD = 0.30) 
logMAR. As described in Chapter 3, the VA was taken from the hospital notes, 
therefore may have been different than if it had been measured on the day of 
the assessment. Among the questionnaires completed by these patients was the 
EQ-5D-5L for which utility scores were calculated using the EQ-5D-5L interim 
value-set for the UK. 
The mean utility predicted by the algorithm was 0.658 compared with the mean 
utility derived from the EQ-5D of 0.613 (the algorithm predicted an average of 
+0.045 compared with the actual EQ-5D scores). However, when individual 
patient scores and predictions are compared (Figure 6.19), it can be seen that 
although the trend line of the algorithm is sloping in the expected direction 
(higher utility scores correlate with higher predicted utility), the algorithm is 
considerably over-predicting low utilities and under-predicting high utilities. 
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Figure 6.19. Validation (actual vs. predicted utility scores in independent sample) 
 
Utility values from the model were compared with published data. For a 70 year 
old with wet AMD, the algorithm predicted a utility of 0.48 for a VA of 2.00 and 
0.81 for a utility of 0.30. 
The range of utilities predicted was greater than for EQ-5D utilities elicited by 
Espallargues et al. (which reported 0.63 and 0.75 respectively). Compared with 
the contact lens simulation by Czoski-Murray et al., utilities were marginally 
higher across VA with a similar range. (Table 6.33) 
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VA Utility (EQ-5D, 
Espallargues et al.) 
Utility (contact 
lens simulation) 
Predicted by 
algorithm* 
>2.00 0.63 
0.314 
0.48 
1.31 to 
2.00 
0.71 0.48 – 0.61 
0.61 to 
1.30 
0.75 0.511 0.61 – 0.75 
0.31 to 
0.60 
0.70 0.681 0.75 – 0.80 
≤0.30 0.75 0.706 0.81 
Table 6.33. Comparison with published utility values. 
*70 year old with wet AMD 
 
6.3.4. Conclusion 
These results should be considered exploratory due to the small sample size. Of 
the three measures of visual function, VA appears to be the best predictor of 
utility in patients with advanced AMD. Age and diagnosis also contribute to 
predicting utility. 
CS and microperimetry did not predict utility in this dataset. Reasons for the 
weak association between these measures of visual function and utility may 
include the impact of comorbidities on health status and the insensitivity of the 
EQ-5D questionnaire to different levels of visual function. Furthermore, only 
around a third of the estimated sample size was used in this analysis meaning 
that the models may be underpowered. 
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The algorithm performed poorly at extreme upper and lower utility values. Such 
a result could be expected given that visual function cannot predict 
comorbidities, which may cause extreme low values of utility. 
Improved methods for excluding comorbidities may improve the association in 
small samples (particularly at extreme values). However, since the recording of 
comorbidities in clinical trials is not standardised, their exclusion from the 
model means that it may be used in a wider range of datasets. Indeed, the 
variables included in the algorithm (VA, age and diagnosis) are routinely 
available in clinical practice, therefore provide the most useful algorithm for 
calculating utility values for historic trials where utilities were not originally 
collected. 
Furthermore, most interventions for visual disorders are likely to affect only the 
components of utility captured by the algorithm, therefore the algorithm can be 
expected to measure the incremental utility change due to vision whether or not 
it includes comorbidities.  
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7. CUA of treating patients with early AMD 
This chapter develops a CUA model to investigate the cost effectiveness of 
treating AMD patients with early disease, and therefore better vision than the 
published NICE guidance, using a database of real world outcomes in order to 
address research aim 4: What is the economic impact of treating AMD patients 
with good starting vision? 
 
7.1. Introduction 
Intravitreal injection of anti-VEGF drugs such as ranibizumab (Lucentis, 
Novartis) is an established therapy to treat nAMD and is the most commonly 
performed retinal procedure in the UK NHS.(118) In the UK NICE recommended 
the use of ranibizumab for nAMD in August 2008, leading to almost exclusive 
usage of ranibizumab for nAMD in the UK NHS.(73) In addition to the 
limitations of evidence on utility investigated in previous chapters, there is an 
absence of information on the effectiveness and cost effectiveness of treating 
AMD patients with good starting levels of vision. 
Clinical and economic evidence was initially informed by the Anti-vascular 
endothelial growth factor Antibody for the Treatment of Predominantly Classic 
Choroidal Neovascularization in Age-related Macular Degeneration (ANCHOR) 
and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in 
the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) 
Studies, which demonstrated that ranibizumab prevents central vision loss and 
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improves mean VA at 2 years when given at monthly intervals in eyes with 
subfoveal nAMD.(119, 120) 
Consistent with these pivotal studies, NICE recommended that ranibizumab for 
nAMD should be funded in eyes presenting with VA’s between 6/12 and 6/96, 
which parallels the entry criteria of the pivotal studies. Due to the trials’ 
exclusion criteria, no direct evidence exists from Phase 3 randomised controlled 
clinical trials to assess the effectiveness and cost effectiveness of treating 
patients presenting with early lesions resulting in vision better than 6/12. 
However, patients have been presenting with nAMD to treating centres with 
better visions since NICE initially supported ranibizumab reimbursement on the 
NHS in 2008. Current guidance is to wait until vision worsens to below 6/12 
before treating. It has previously been shown that if ranibizumab therapy is 
initiated in eyes with good visual acuities the treated eye is more likely to 
maintain good vision and this is consistent with the indirect evidence from the 
pivotal trials that eyes are more likely to maintain vision than recover lost 
vision at initiation of treatment.(119, 120) 
The purpose of this chapter is to evaluate whether immediate intervention with 
ranibizumab in the better seeing eye of patients presenting with nAMD with 
good vision is cost effective compared with the delayed intervention approach 
that is currently recommended. 
A health economic model with health states based on levels of VA in the better 
seeing eye was developed. The intervention considered is the initiation of 
ranibizumab (10mg/ml solution for injection) treatment using 3 loading 
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injections + a PRN protocol for patients with a confirmed diagnosis of nAMD 
and vision better than 6/12: immediate treatment. The comparator is the 
current standard of care for nAMD patients, which is no treatment for patients 
with a confirmed diagnosis of nAMD with vision better than 6/12 and treatment 
with ranibizumab using 3 loading injections of ranibizumab at approximately 
monthly intervals followed by a pro re nata (3 loading injections + PRN) 
protocol when vision falls below 6/12: delayed treatment (current NHS 
practice). Effectiveness and resource use was derived from real life outcomes 
from treated and untreated (fellow) eyes in 14 centres using ranibizumab for 
AMD in the UK.(121) 
This analysis is the first to assess the cost effectiveness of treating VA better 
than 6/12 in nAMD compared to treating only when vision is worse than 6/12 
with ranibizumab. Furthermore, the work demonstrates how real world 
outcomes and resource use associated with the use of ranibizumab therapy may 
be used to assess the cost effectiveness of treating nAMD.  These results may be 
more generalizable to routine clinical practice than models based on 
randomised controlled trial (RCT) data, therefore more appropriate to assess 
the cost effectiveness of routine use treatment protocol in the NHS.  
 
7.2. Methods 
Model structure 
A Markov patient level simulation model was developed with an initial 3 month 
cycle followed by monthly cycles. The model consisted of six health states: five 
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health states defined by declining VA ranging from 6/15 or better (least severe) 
to less than 3/60 (most severe), and an additional absorbing state, death, which 
was accessible from all levels of vision. VA was used for this model as it was the 
only visual function measure routinely captured in the EMR database. (Figure 
7.20) 
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Figure 7.20. Model structure. 
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On entering the model, a patient was assigned an age and gender based on the 
distribution of these characteristics among patients with a starting vision of 
better than 6/12 in the dataset. 
For immediate treatment, a patient was simulated to be treated straight away 
on confirmed diagnosis of nAMD with 3 initial monthly ranibizumab injections 
followed by PRN for 2 years. For delayed treatment, a patient was assigned a 
time from diagnosis to vision falling below 6/12. In the initial period (>6/12) a 
patient received no treatment. After reaching 6/12, treatment began and a 
patient progressed to a state of vision assigned according to a distribution based 
on the visions of patients beginning treatment in the dataset (i.e. many eyes 
with nAMD will initially present with a vision in the NICE guidance allowing 
immediate treatment but the vision may be any value between 6/12 and 6/96 
and not just 6/12). A patient was then treated with 3 initial monthly 
ranibizumab injections followed by PRN and continued through the model for 2 
years including the starting delay. The simulation was run for 10,000 patients. 
Perspective 
The perspective of the model was the UK NHS and personal social services as 
recommended in the NICE Guide to the Methods of Technology Appraisal 
reference case.(2) The model had a two year time horizon, which represented 
the time horizon used in pivotal trials. Due to the short time horizon, costs and 
benefits were not discounted. 
Transition probabilities 
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Transition matrices were calculated from the EMR dataset (Table 7.34). Data 
were ordered longitudinally from the first visit for a ranibizumab injection. 
Since patients returned for injections at a frequency determined by their 
clinician, there were a large number of time points with missing outcome data. 
Linear interpolation was conducted in Stata 12 (StataCorp) to estimate VA at 
time points that were missing between measured VA. 
For treatment, transitions were calculated from visual acuities recorded for 
treated eyes. For no treatment of eyes better than 6/12, transitions were 
calculated from visual acuities recorded for fellow (untreated) eyes. 
In the immediate treatment arm, all patients began in state >6/12 with a three-
month loading dose cycle. Patients then received ranibizumab PRN with 
monthly transitions for the remainder of the two years. 
For the delayed treatment arm, patients followed a time-to-event survival curve 
to define the time in state >6/12 before dropping below 6/12 and beginning 
treatment. Once their vision dropped below 6/12, they entered the three-month 
loading dose cycle in the following distribution [state 1: 0, state 2: 0.434484, 
state 3: 0.3891544, state 4: 0.1456472, state 5: 0.0307501 (based on the 
distribution of patients beginning treatment in the dataset)]. Patients then 
received ranibizumab PRN with monthly transitions for the remainder of the 
two years.  
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A. Immediate treatment 
First 3 months 
(M 0-2), prob. for 
3M cycle 
To 6/6 - 
>6/12 
6/12 - 
6/24 
6/24 - 
6/60 
6/60 - 
3/60 
<3/60 
From 6/6 to  
>6/12 
.7240 .2222 .0335 .0108 .0096 
  
Remainder of 2 
years (M 3-24), 
prob. for 1M 
cycle 
To 6/6 to 
>6/12 
6/12 to 
6/24 
6/24 to 
6/60 
6/60 to 
3/60 
<3/60 
From 6/6 - >6/12 .8778 .1163 .0046 .0006 .0008 
6/12 - 6/24 .2937 .6243 .0783 .0032 .0005 
6/24 - 6/60 .0359 .2355 .6747 .0479 .0060 
6/60 - 3/60 .0219 .0146 .1533 .7007 .1095 
<3/60 .0588 .0147 .0147 .2059 .7059 
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B. Delayed treatment 
First 3 months (M after 
drop to state 2), prob. 
for 3M cycle 
To 6/6 - 
>6/12 
6/12 - 
6/24 
6/24 - 
6/60 
6/60 - 
3/60 
<3/60 
From 6/6 - >6/12 .0 .0 .0 .0 .0 
6/12 - 6/24 .3300 .4993 .1506 .0139 .0062 
6/24 - 6/60 .0699 .3049 .4923 .1057 .0272 
6/60 - 3/60 .0157 .0927 .3795 .4123 .0999 
<3/60 .0203 .0541 .2432 .4257 .2568 
  
Remainder of 2 years (+ 
3 from M after reaching 
state 2), prob. for 1M 
cycle 
To 6/6 - 
>6/12 
6/12 - 
6/24 
6/24 - 
6/60 
6/60 - 
3/60 
<3/60 
From 6/6 - >6/12 .7366 .2408 .0139 .0026 .0062 
6/12 - 6/24 .1433 .7161 .1341 .0054 .0011 
6/24 - 6/60 .0081 .1414 .7369 .1068 .0068 
6/60 - 3/60 .0047 .0093 .2018 .7045 .0797 
<3/60 .0380 .0087 .0459 .2985 .6089 
Table 7.34. Transition probabilities between health states. A. Immediate treatment. B. Delayed 
treatment 
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Utility 
Benefits were measured in QALYs. VA was converted to utility for the 
calculation of QALYs using Brown et al., which elicited utilities in 80 patients 
AMD using the TTO method and grouped these by the VA health states defined 
in the model.(48) Brown et al. was selected for comparability with the utility 
values and health states used in the original NICE appraisal of ranibizumab that 
recommended the treatment for patients with vision better than 6/12. 
The health state utility values used in the model are reported in Table 7.35. 
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VA Utility, mean (SD) 
From 6/6 to 6/12 0.89 (0.16) 
6/12 to 6/24 0.81 (0.20) 
6/24 to 6/60 0.57 (0.17) 
6/60 to 3/60 0.52 (0.24) 
<3/60 0.40 (0.12) 
Table 7.35. Utility values for model health states. 
*from Brown et al.(48) 
 
Cost 
Resource use and costs were applied to reflect UK clinical practice. Resource use 
consisted of monthly assessment visits and ranibizumab injection. On initiation 
of treatment, patients received three loading doses of ranibizumab as 
recommended by clinical guidance followed by PRN injections at a frequency 
calculated from the dataset. 
UK unit costs were assigned for a cost year of 2012. A cost of ranibizumab of 
£742.17 per injection, an assessment cost of £255.00 and a monitoring cost of 
£60.00 was used.(122, 123) These costs were consistent with the NICE costing 
template for Aflibercept (July 2013).(124) 
Sensitivity analysis 
Appropriate probability functions were fitted to model parameters to 
incorporate uncertainty. Probabilistic sensitivity analysis was performed using 
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a Monte Carlo simulation to randomly sample each parameter. Utilities were 
characterised by a beta distribution, with alpha and beta parameters defined by 
the means and standard deviations of the utilities. Costs were characterised by a 
gamma distribution with alpha and beta parameters defined by the means and 
standard deviations of the costs. Standard deviations were not available for 
costs, therefore they were assumed to be 10% of the mean in line with 
recommended practice for health economic models. Transition probabilities 
were characterised by a Dirichlet distribution. A CEAC was constructed to 
represent the probability of the treatment proving cost effective at a given value 
of health effect. One-way sensitivity analysis was employed to test structural 
uncertainty within the model. 
EMR data set 
Transition probabilities and resource use were calculated from a large dataset 
of ranibizumab injections which covered data from the approval of ranibizumab 
in August 2008 until April 2012.(121) Data were extracted on 12,951 eyes of 
11,135 patients receiving a total of 92,976 ranibizumab injections during 
317,371 clinic visits at 14 UK hospitals. At two years, 4,420 patients remained in 
the analysis, at 4 years, 526 patients remained in the analysis. The relatively 
steep drop-off is due to patients being discharged when ranibizumab is deemed 
to be no longer effective. 
14 NHS hospitals that deliver ranibizumab AMD treatment services in England 
and Northern Ireland submitted data to this study. Each site is the only NHS 
provider of nAMD care to their local population and very few patients switch 
between providers. Following NICE approval for the use of ranibizumab for 
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nAMD in the NHS in August 2008 all sites used this drug almost exclusively. The 
lead clinician and Caldicott Guardian (who oversees data protection) at each 
centre gave written approval for the data extraction. Patient identifiers were 
completely stripped out and site and clinician data were pseudo-anonymised 
and on this basis an ethics committee determined that formal ethics approval 
was not required. This study was conducted in accordance with the declaration 
of Helsinki and the UK’s Data Protection Act 
The 14 sites entered their first treatment episodes into the EMR system during 
the following years: 2006 (n=2 sites), 2007 (n=5), 2008 (n=4), 2009 (n=1), and 
2010 (n=2). The first recorded ranibizumab injection was dated November 
2006.  
Over the period of data collection, anti-VEGF treatment was performed in 
13,774 patients, of whom 2,639 received anti-VEGF for reasons other than 
nAMD or received bevacizumab. Thus this study analyses data on 12,951 eyes of 
11,135 patients who received a total of 92,976 ranibizumab injections during 
317,371 clinic visits at 14 UK hospitals. 16.3% (n=1,816) of these patients 
required treatment to both eyes during the follow up period. The demographics 
of the patients included have been published elsewhere and are summarised in 
Table 7.36.(121) 
‘Best-measured VA’ was the best VA with refraction or habitual correction 
and/or pinhole as measured on an Early Treatment Diabetic Retinopathy Study 
(ETDRS) chart and expressed as ETDRS letters and LogMAR vision in this study.  
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Variable Male (n = 
4,071) 
Female (n = 
7,062) 
Not specified 
(n = 1) 
Total (n = 
11,135) 
Age (years)     
Mean 78.8 80.1 79 79.7 
Median 80 81 79 81 
IQR 74-84 76-86 - 75-85 
Range 55-103 55-108 - 55-108 
Table 7.36. Demographic details of patients used to develop model. 
*IQR = interquartile range 
 
Missing data 
For patients where data were not available for a particular visit or had been lost 
to follow-up no missing value substitutions were performed. The only exception 
to this rule was baseline VA as some treatment centres brought patients back 
for a 2 stop service—assessment on first visit followed by injection on second 
visit, and did not repeat VA measurements on the date of the first injection 
(n=1670), which was always performed within 3 weeks. This was therefore not 
missing data per se but reflects variation in treatment delivery. 
  
7.3. Results 
The central ICER estimate from PSA was £4,251.60 per QALY for immediate 
intervention compared with delayed intervention.(Table 7.37) In the 
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immediate intervention group, patients accumulated on average 1.59 QALYs 
and £8,469.79 costs over two years versus 1.35 QALYs and £7,460.21 costs in 
the delayed intervention group. 
Figure 7.23 shows the cost effectiveness plane with 10,000 simulations. The 
majority of the distributions are located to the lower right of a £20,000 
willingness to pay threshold. The results are disaggregated into the incremental 
cost per QALY of immediate intervention and delayed intervention in Figure 
7.22. 
Figure 7.24 shows the CEAC. Immediate treatment has a 50% chance of being 
cost effective compared with current treatment practice if the NHS were willing 
to pay £4,251.60 per QALY. At a willingness to pay threshold of £20,000 per 
QALY, immediate treatment has a >90% chance of being cost effective. 
One-way sensitivity analysis is reported in Table 7.38. The model was sensitive 
to time horizon. Running the model for five years rather than two resulted in a 
lower ICER of £1,773.21 (58% lower than the base case). Over a longer time 
horizon, the early intervention arm accumulated more QALYs for a marginally 
higher cost than the delayed intervention arm. A younger starting age had a 
marginal impact on the ICER, with a starting age of 60 years generating an ICER 
of £3,909.36 (8% lower than the base case). Including only drug cost (no visit 
cost) led to an ICER of £3,697.82 (13% lower than the base case). The ICER was 
also impacted by the choice of health state utility values. Using values elicited by 
Brown et al. using the standard gamble technique generated an ICER of 5,126.51 
(21% higher than the base case using TTO values from the same source). 
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 Comparator 
(delayed 
intervention) 
Intervention 
(immediate 
intervention) 
Incremental 
Cost £7,460.21 £8,469.79 £1,009.58 
QALYs 1.35 1.59 0.24 
ICER  £4,251.60 
Table 7.37. Central cost-effectiveness results: average of Monte Carlo analysis.  
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Figure 7.21. Proportion of patients in health states over time. 
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Figure 7.22. Costs and QALYs accumulated over two years by patients treated with ranibizumab 
according to current NHS practice (red) and with early intervention (blue). 
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Figure 7.23. Cost-effectiveness plane. GBP = British Pounds. 
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Figure 7.24. Cost-effectiveness acceptability curve of immediate treatment of nAMD with 
ranibizumab (dark grey) compared with current NHS practice of delayed treatment (light grey). 
  
7.4. Discussion 
Immediate intervention in nAMD is likely to be a cost effective strategy. Over 
two years, patients received an average of 1 more injection and gained 0.24 
QALYs compared with current practice of delayed intervention. 
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The ICER of £4,251.60 of treating early versus current treatment practice is 
substantially below a threshold of £20,000 per QALY which is often considered 
the NHS’ willingness to pay for health gain.(125) 
This is believed to be the first assessment of the cost effectiveness of treating 
patients with ranibizumab with vision better than 6/12. It appears that the 
recommendation of treating patients with vision worse than 6/12 was based on 
the absence of evidence in patients with better vision due to the exclusion 
criteria in clinical trials of ranibizumab. Therefore, NICE currently do not 
recommend funding for eyes with good VA, which may result in some patient 
having to drop below 6/12 to initiate therapy. From a patient perspective, what 
is more important is maintaining a good functional visual state that allows 
continuing to be able to read and drive and waiting until the vision falls below 
6/12 can be anxiety provoking and delayed treatment can result in worse 
clinical outcome.(126) This chapter provides evidence that early ranibizumab 
treatment is associated with a small incremental cost per QALY within the range 
that the NHS is typically willing to pay for health gain. 
As the first assessment of the cost effectiveness of treating a broader range of 
visual acuities with ranibizumab, the results cannot be directly compared with 
other models. In NICE’s economic evaluation of ranibizumab for AMD, the 
assessment group used a similar state transition model based on VA.(73) The 
base case ICERs over a10-year time horizon for predominantly classic lesions 
were £15,638 per QALY gained compared to PDT with verteporin, and £11,412 
per QALY gained compared with best supportive care. For minimally classic 
lesions and occult lesions, assuming 2 years of treatment, the ICER was £25,098 
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per QALY gained compared with best supportive care. In terms of clinical 
effectiveness, VA outcomes from the database previously reported that 
outcomes do not match the results achieved in most randomized trials, but they 
were delivered with substantially fewer injections and hospital visits.(121) 
This study synthesises outcomes from routine NHS treatment, which is likely to 
better reflect real world effectiveness and resource use than RCT evidence. 
Beyond the limited range of visual acuities included in pivotal trials, the use of 
RCT data for assessing cost effectiveness suffers from limitations of 
inclusion/exclusion criteria and protocol-driven treatment patterns. Thus, the 
outcomes and treatment practices derived from RCT data may not reflect 
today’s clinical practice. By contrast, the use of real world data requires robust 
methods to deal with non-standardised aspects such as missing data. 
There are a number of limitations to this study beyond the need to use VA alone 
as mentioned in the Methods section. First, the study required some 
assumptions to be made about changes in vision that occur between patients 
not being treated, which we derived from natural history data, and patients 
beginning treatment, which we derived from the EMR dataset. Once the delayed 
treatment group initiates therapy, they immediately fall to the starting VA of 
any person starting on treatment. Meaning that once they fall below the 6/12 
line their VA state changes to match the distribution of starting VA in the 
dataset of anyone beginning treatment. We believe that this is realistic in 
clinical practice, since most lesions are likely to have subtle changes that can be 
seen clinically before the patient notices it or they qualify for treatment. The 
survival curve on which the model is due to the fellow eye’s structural optical 
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coherence tomography (OCT) data in the EMR dataset. Once the lesion causes 
the vision to fall below 6/12 patients could realistically end up in any possible 
vision clinically. 
Second, due to the limited number of VA states, a significant number of patients 
in the treat-early group remain in the best VA state for the lifetime of the model. 
Such a situation is perhaps not surprising: Ranibizumab treatment is generally 
associated with a maintenance of vision rather than an improvement (recovery 
of lost vision due to nAMD). Therefore in the model initiating treatment early, 
patients maintained a better VA state and accumulated more QALYs.  
In summary, this study provides real world data based model demonstrating 
that early ranibizumab intervention is associated with an acceptable 
incremental cost that is well within the NHS acceptable range to pay for health 
gain. Thus, the maintenance of better VA in patients who are treated early is not 
only beneficial clinically but also likely cost effective. This study may help 
inform future policy decision regarding the routine treatment with ranibizumab 
at VAs better than 6/12.  
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8. Valuing The Benefits Of Decision Support Tools 
 
This chapter presents a conceptual framework to assess the value of decision 
support tools in order to address research aim 2: Are non-health attributes 
important in AMD and how can they be incorporated into the cost-utility economic 
evaluation framework? 
8.1. Measuring the economic benefits of process 
Decision support tools are increasingly used within the health care system. 
Their application may be to enhance the shared doctor-patient decision-making 
process or to allow patients to access information at their own leisure rather 
than within the constraint of a time-limited consultation. Alternatively, patients 
may not need a trained physician to understand some more simple health 
decisions and their use may allow limited physician resources to be reemployed 
to more complex, more valuable tasks. 
Despite these hypothesised benefits, economically evaluating the use of decision 
support tools provides a challenge for CUA using QALYs, the dominant 
framework used to conduct economic evaluation of health technologies. 
Decision support tools have a cost, but they are rarely implemented with the 
sole or even primary aim of generating a health benefit, so their impact on 
QALYs is difficult to quantify. 
To date, a small number of evaluations have assessed decision support tools in 
terms of cost: a systematic review of the impact of decision support tools on 
costs to the health care system concluded that although patients chose more 
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conservative disease management options, there was limited evidence , that 
implementing decision support interventions generated savings for the 
system.(127) 
On the effect side, assessments of the benefits of decision support tools have 
focused on reporting improved patient knowledge, experience and satisfaction. 
A review of 86 randomised trials of decision aids found decision aids increase 
people’s involvement, and improve knowledge and realistic perception of 
outcomes.(128) 
Decision support tools are rarely subjected to economic evaluation with a view 
to their opportunity cost despite having recognised cost-effectiveness 
implications for the health care system and for patients. This is at odds with 
increasingly rigorous methods being applied to assess the cost-effectiveness of 
other health technologies.(2) 
A major reason for this is that the current methodological toolkit is unsuited to 
assessing them. The lack of a directly measurable health benefit may make 
decision makers wary of exposing decision support tools to the rigors of HTA 
processes. In a review of the impact of information provision on the HRQoL of 
cancer survivors, only one of eight studies of interventions to increase health 
information showed a positive impact on HRQoL.(129) Furthermore, a trial of 
shared decision-making and risk communication aids found that neither had an 
impact on patient health outcomes, yet concluded that arguments for the 
techniques can be made from values and ethical principles set against cost.(130) 
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In a resource-constrained health care system there is a need for the costs and 
benefits of interventions to be assessed in a manner that has cross-programme 
comparability in order to assess the opportunity cost of the forgone alternative 
in order to make the best use of limited resources.(1) Furthermore, the use of 
decision support tools may be desirable from an ethical and legal perspective. In 
the USA, Washington State, a bill was passed that recognises the role of decision 
aids in facilitating a higher legal standard of obtaining informed consent.(131) 
This chapter begins by considering the assessment of benefits of decision 
support tools within the context of CUA, the dominant framework used by HTA 
agencies for economic evaluation. Limitations of this framework for the 
assessment of decision aids are identified. An alternative framework for the 
economic evaluation of decision support tools is proposed and the issues 
required to operationalize the approach are discussed. 
For the purposes of this chapter we define a decision support tool as a system to 
help patients understand their disease management options in order to make an 
informed health care decision with their physician, either for the patient alone 
or for the patient and physician to use together. An example of the former is the 
CatInfo, which is a computer program for prospective cataract surgery patients 
to use prior to the informed consent process. CatInfo has been shown to 
increase patient knowledge of cataract surgery.(132) 
 Decision support tools may also refer to systems for physicians to better 
interact with patients and raise relevant issues. While these may have similar 
benefits for the patient in terms of improved decision making, these tools are 
related to improving the effectiveness of physicians themselves, and can be 
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viewed as a separate concept falling within the context of physician training. 
From a measurement point of view, a patient will find it harder to distinguish 
between the performance of a physician using the tool and their performance 
without it. 
 
8.1.1. Current framework: health benefits 
Within QALY-based CUA, health benefit can be achieved through improvements 
in quality of life or length of life. The purpose of a decision support tool is 
generally to improve the decision making process to enable a physician and 
their patient to come to the best choice among management options with 
uncertain outcomes. 
The increased understanding of relative risks and benefits associated with each 
management option can be expected to result in proportionally more patients 
choosing the decision that is associated with the largest health gain. Such a 
situation will show up in CUA as a greater QALY gain: 
𝐸𝑈 = 𝑎 (𝑢𝑛𝑐𝑒𝑟𝑡𝑎𝑖𝑛𝑡𝑦) 𝑥 𝑏 (ℎ𝑒𝑎𝑙𝑡ℎ 𝑔𝑎𝑖𝑛) 
Where EU = expected utility and the decision support tool influences the level of uncertainty 
through a. 
 
Robinson & Thomson developed an expected utility approach for use within a 
decision analysis framework in order to integrate patient preferences with 
probabilistic information, which builds on the above methodology. They lay out 
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the standard gamble as a technique for eliciting preferences for atrial fibrillation 
and warfarin anticoagulation.(133) 
 
8.1.2. Limitations with current framework 
1. Non-health benefits: 
The above framework appears to lead the definition of a good decision towards 
the one that produces the greatest health gain. However, the outcomes 
associated with use of a decision support tool are broader. 
Of 86 studies of decision support tools identified in the review, 63 assessed one 
or more of knowledge scores (51); accurate risk perceptions (16); and informed 
value-based choice (12); feeling informed (30) and feeling clear about values 
(18). The impact of the decision aids on general or condition-specific health was 
only measured in 7 and 9 of the 86 trials respectively and decision aids did not 
appear to have an effect on health attributes. None of the 86 studies identified in 
a recent review included preference-based health outcomes.(128) 
A focus on health gain alone is not necessarily consistent with the broader aims 
of physicians employed in the agency relationship. Agents are there to reduce 
the information gap present when patients make health care decisions or to act 
on patients behalf by assuming their values.(134) These two concepts have 
been articulated in the decision making literature by Bekker et al. who 
considered an informed decision to be one “using relevant information about 
the advantages and disadvantages of all possible courses of action” (informed) 
and “in accordance with personal beliefs” (based on the patient’s values).(135) 
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Vick & Scott highlighted the complexity of the agency relationship. They 
identified that being able to talk to the doctor was the most important attribute. 
Patients tended to prefer more information to less, but only females and highly 
qualified respondents wanted to choose their own treatment.(136) 
In the current framework, the role of the decision tool is to reduce uncertainty 
in order to realise a greater QALY gain. As discussed, it is unclear that the 
objective of health gain is the only or even the main aim of the tool. By excluding 
other benefits within the broad umbrella of process of care, the utility of 
decision support tools are likely to be undervalued. 
2. Measuring uncertainty: 
The above framework is grounded in expected utility theory (vNM utility 
theorem), which is considered to be a realistic representation of how health 
care decisions are made in practice.(4) 
The long-term objective of health gain through reduced uncertainty is 
challenging to measure and associate with the decision. While a treatment and 
health effect are easy to correlate, the initial decision choice between disparate 
treatment options is harder to associate with the health effect. The extra step 
may make ex ante uncertainty-based utility a less reliable proxy of realised 
utility in the context of deciding a treatment, compared with the treatment itself. 
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8.1.3. New framework: consultation time 
A new approach to measuring the benefits of decision support tools should 
address the issues of the difficulty measuring the uncertainty and the additional 
objectives of decision support tools. 
A more suitable approach is to consider what activity is displaced in the health 
care system. A decision support tool may be seen as a substitute for physician 
time. The aims of a physician are broader than maximising health and it is 
unlikely that a physician consultation would be fully assessed in a formula of 
reducing uncertainty to increase realised QALYs. As well as improving the 
health of a patient in the long term, in the short term, they are a provider of 
information and a reducer of anxiety regardless of the potential for health gain. 
Indeed, the agency model of the doctor-patient relationship assumes that 
physicians are employed by a patient to reduce the information gap between 
the patient and the disease management options.(136) 
By considering the decision support tool in terms of the opportunity cost of 
physician consultation and as a substitute for physician time, an approach of 
valuing the tool against the next best alternative is likely to capture a more 
direct measure of the benefit and include more attributes than health 
uncertainty. Applying this to decision making gives: 
EU = a (Physician consultation) + b (Decision support tool) 
 
Where EU is the expected utility of the consultation process and physician time 
and the decision support tool are perfect substitutes. 
 214 
The Consultation Time Trade-Off (CTTO) requires the patient to choose 
between use of the decision support tool and varying lengths of consultation 
time with a physician before they reach the point of indifference. A ping-pong 
technique within a hypothetical ten-minute consultation may be used as 
described in Figure 8.25. Ten minutes has been chosen as a length that patients 
will be familiar with for a consultation. The output of the CTTO will be a number 
of minutes that the patient would be willing to trade for use of the tool, 
equivalent to the opportunity cost of the tool expressed by its displaced 
alternative: physician consultation time. 
 
I would like you to imagine a situation in which you are about to undergo [your treatment 
decision] for the first time. You are given the choice of either having a consultation with your 
doctor for a maximum of 10 minutes or alternatively using the [decision support tool] for all or 
part of this process. 
Please imagine that 10 minutes with your doctor is the amount of time required to explain the 
treatment options and answer any questions you may have to your satisfaction. 
Based on your knowledge of [the decision support tool], you have the choice of a shorter 
consultation with your doctor or to use the [decision support tool] for as long as you would like. 
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Figure 8.25. Consultation time trade-off: Introduction and first three questions. 
 
The approach follows the widely used TTO,(137) which is commonly used to 
elicit health preferences and forms the basis of the EQ-5D utility scale.(18) 
 
8.1.4. Application to economic evaluation 
The number of minutes can be assessed against the cost of the tool (likely to be 
calculated as cost of use and an appropriate proportion of implementation). 
Such a value may be informative to give an indication of the amount of physician 
time that can be saved and re-deployed to more complex tasks elsewhere in the 
health care system. 
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Alternatively, the number of physician minutes saved can be converted to a 
monetary value using the local wage rate of the physician that would have been 
employed on the task. This can then be put against cost in a cost benefit analysis 
that is comparable across health care programmes. 
The preferences derived from the CTTO are those of the patient. Due to the 
unique combination of attributes of each decision support tool, direct user 
experience is required to make an accurate trade-off. In contrast economic 
evaluation of health technologies is often recommended from the public 
perspective using general public preferences for health states expressed from 
behind a ‘veil of ignorance’.(7) This difference may limit the direct 
comparability of economic evaluation of decision support tools using the CTTO 
with those using other measures that take the public perspective. 
 
8.1.5. Further questions to refine new framework 
Converting to a monetary value has implications in terms of the marginal value 
of a consultation to a patient. The cost to the health care system of a physician 
consultation is constant, so from the health care system perspective, the 
monetary value of the consultation is constant. However, it may be the case that, 
from the patient perspective, the ideal consultation should have a diminishing 
marginal utility because the patient should have their most important questions 
answered first. However, constraint on consultation time may make this less 
likely. Further work would be recommended on the marginal value of a 
consultation if the monetary measure is to be described as a patient value. 
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The time at which the CTTO is asked requires consideration in relation to ex-
ante and ex post utility. By asking soon after the decision support tool has been 
used, patients are likely to have the clearest recollection of it. Having said this, 
the full evaluation of the tool may incorporate the implications of the decision, 
for example after the patient has undergone the elective surgical procedure and 
the health consequences have been realised. The former, ex ante, application 
would be recommended for consistency with expected utility theory. Use of the 
CTTO after the health consequences have been realised would derive 
experience utilities,(138) which cannot be considered consistent with expected 
utility used in other health care decision making contexts. 
The value of the use of decision support tools is likely to be influenced by the 
patient’s  own attitude towards making their own health care decisions 
compared with delegating the decision to their physician agent. The Degner 
scale may be a useful measure to prospectively determine if the patient is likely 
to benefit from use of a decision support tool or retrospectively stratify cost 
benefit results of the tool into subgroups of patients.(139) 
 
8.1.6. Conclusion 
The framework of QALYs is ill-suited to the economic evaluation of health care 
decision making due to non-health attributes of the decision making process 
and the gap between a decision and the future health gain (or loss). A new 
approach based around physician consultation time allows decision support 
tools to be assessed within the framework of opportunity cost, which has the 
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potential to support a more effective allocation of resources within the health 
care system. 
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9. Conclusion 
 
The significant and progressive impact on health-related quality of life of the 
disease makes the accurate calculation of utility values for economic evaluation 
important. This thesis has investigated approaches for the measurement and 
valuation of health in AMD. Four research aims were identified to investigate 
current methods for measuring and valuing health and develop improved 
methods: 
1.How do widely used methods for deriving health state utility values in AMD 
perform and how can these methods be improved? 
2.Are non-health attributes important in AMD and how can they be incorporated 
into the cost-utility economic evaluation framework? 
3.How is visual function associated with utility in AMD and how can the 
association be applied to economic evaluation? 
4.What is the economic impact of treating AMD patients with good starting vision? 
 
Findings 
 How do widely used methods of deriving utility values in AMD 
perform and how can these methods be improved? 
Chapter 3 reported the valuation of the performance of commonly used PROMs 
and health state valuation techniques. It identified limitations in the utility 
values used to estimate QALYs in AMD. Patient preferences for health states 
associated with AMD were found to differ substantially from public tariffs. Using 
simulation contact lenses to inform the public about the impact of AMD prior to 
valuation was found to be invalid as the contact lenses did not generate a 
central scotoma characteristic of AMD.  
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Chapter 4 reported a study augmenting the EQ-5D descriptive system with 
AMD disease descriptions. It demonstrated that different utility values may be 
elicited for health states when using different information and framing in the 
TTO valuation task. 
 Are non-health attributes important in AMD and how can they be 
incorporated into the cost-utility economic evaluation framework? 
Chapter 5 developed weightings for utilities by other attributes and shown that 
members of the public value non-health attributes such as severity and process 
of care and are willing to forgo some health gain to prioritise these attributes. 
Chapter 8 developed a theoretical framework for the evaluation of decision 
support tools for treatment choices in vision. 
 How is visual function associated with utility in AMD and how can 
the association be applied to economic evaluation? 
Chapter 6 investigated the association between different aspects of visual 
function and utility values in AMD. It demonstrated that using contrast 
sensitivity in economic modelling results in different cost-effectiveness 
estimates to visual acuity, which has been most commonly used to date. 
It also showed the potential for a mapping algorithm between visual function 
and utility that could be applied to perform cost effectiveness analysis using 
trials that have not recorded utility values. 
 What is the economic impact of treating AMD patients with good 
starting vision? 
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Chapter 7 employed a CUA model to assess the cost effectiveness of the 
treatment of early AMD currently outside UK guidance using real world 
outcomes data. It demonstrated that early treatment is associated with a 
modest incremental cost per QALY. 
Future research 
During the course of the thesis, the Euroqol Group has developed a bolt-on for 
the EQ-5D (the EQ-5+V).(140) Whilst this questionnaire is still to be validated in 
patients, it may offer a promising alternative to the standard EQ-5D for deriving 
utilities for vision interventions. 
There remain several challenges which need to be addressed in order to 
accurately assess the cost effectiveness of interventions for vision disorders. 
Firstly, the association between utility and visual function measures remains 
important, both for trials that do not contain suitable PROs for deriving utility 
and for extrapolating outcomes beyond the end of the trial for vision disorders 
that are life-long conditions. Further work on this may be done with a larger 
sample than used in this thesis. 
Secondly, the measurement and valuation of non-health benefits for 
interventions that may have significant process benefits is increasingly 
important for decision makers as evidence continues to emerge that the public 
are willing to forgo health gain for improvements in other attributes. Further 
work on defining the relevant attributes and incorporating these into economic 
evaluation is warranted. 
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Novel contribution of this thesis to the field of Health Economics 
This thesis demonstrates the lack of validity of widely used methods to derive 
utility values in AMD and therefore suggests that previous economic evaluations 
may have not accurately assessed the economic value of treatments for AMD. 
The thesis provides methodological contributions to the augmentation of health 
state descriptions for preference elicitation. It also develops methods for 
incorporating non-health attributes into economic evaluation by the external 
weighting of QALYs. These may better measure preferences for health states in 
AMD and therefore enable more valid economic valuations of health 
technologies for the condition. 
In terms of impact on patients and practice, as well as developing methods to 
better measure preferences, the thesis demonstrates that the initiation of anti-
VEGF therapy earlier in disease than current guidance is likely to be a cost-
effective use of resources. 
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Survey instruments 
Chapter 3 
EQ-5D 5L sample 
 
 
 273 
 
 
 
 274 
 
  
 275 
SF-12 ‘plus 4’ 
Modified from RAND 36-Item Short Form Health Survey based on Brazier et al. The 
estimation of a preference-based measure of health from the SF-36. Journal of Health 
Economics 21 (2002) 271-292. This survey contains the items of the SF-36 that are used in 
the SF-6D utility algorithm. 
 
This survey asks for your views about your health. This information will help keep track of 
how you feel and how well you are able to do your usual activities. 
 
1. In general, would you say 
your health is: 
Excellent 1 
Very good 2 
Good 3 
Fair 4 
Poor 5 
The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
(Circle One Number on Each Line) 
 Yes, 
Limited a 
Lot 
Yes, 
Limited a 
Little 
No, Not 
limited at 
All 
*3. Vigorous activities, such as running, lifting [1] [2] [3] 
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heavy objects, participating in strenuous sports 
*4. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing 
golf 
[1] [2] [3] 
6. Climbing several flights of stairs [1] [2] [3] 
*12. Bathing or dressing yourself [1] [2] [3] 
During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of your physical health? 
(Circle One Number on Each Line) 
 Yes No 
14. Accomplished less than you would like 1 2 
*15. Were limited in the kind of work or other activities 1 2 
 
During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such 
as feeling depressed or anxious)? 
(Circle One Number on Each Line) 
 Yes No 
*18. Accomplished less than you would like 1 2 
19. Did work or other activities less carefully than usual (Didn't do work 1 2 
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or other activities as carefully as usual) 
 
 
*21. How much bodily pain have you had during the past 4 weeks? 
(Circle One Number) 
None 1 
Very mild 2 
Mild 3 
Moderate 4 
Severe 5 
Very severe 6 
*22. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
(Circle One Number) 
Not at all 1 
A little bit 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
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These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling. 
How much of the time during the past 4 weeks . . . 
(Circle One Number on Each Line) 
 All of 
the 
Time 
Most of 
the 
Time 
A Good 
Bit of the 
Time 
Some of 
the Time 
A Little 
of the 
Time 
None of 
the 
Time 
*24. Have you been a 
very nervous person? 
1 2 3 4 5 6 
26. Have you felt calm 
and peaceful? 
1 2 3 4 5 6 
*27. Did you have a lot of 
energy? 
1 2 3 4 5 6 
*28. Have you felt 
downhearted and 
depressed (blue)? 
1 2 3 4 5 6 
*32. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
(Circle One Number) 
All of the time 1 
Most of the time 2 
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Some of the time 3 
A little of the time 4 
None of the time 5 
 
Thank you for completing this survey 
 
*: goes into SF-6D algorithm 
Red: additional question from SF-36 
Underline: Modified wording  
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Time Trade-Off 
I am going to ask you some theoretical questions, which require careful thought. Please 
take your time to think about your answer. I would like you to compare living in two 
quality of life states for a maximum period of 10 years after which you must assume 
you will die. 
Please consider your overall health today. Imagine that you know with certainty that 
your level of health would remain the same as it is today for 10 years after which point 
you would die. 
Instead of spending 10 years in your current health state, you may instead choose to 
spend a lesser number of years, between 0 and 10, with perfect health and then die. 
(After script, see end for Q9 vision question) 
Script i 
1. If you were given the choice to live for 
10 years in your current state of health or 
to live for 10 years in perfect health, 
which would you prefer? 
a. Perfect health (go to 2) 
b. Current health (stop) 
c. Same (stop) 
 
2. If you were given the choice to live for 
10 years in your current state of health or 
to die immediately (0 years in perfect 
health), which would you prefer? 
a. Immediate death (go to script 
iiia) 
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b. Current health (go to 3) 
c. Same (stop) 
 
3. If you were given the choice to live for 
10 years in your current state of health or 
to live for 5 years in perfect health, which 
would you prefer? 
a. Perfect health (go to script ii) 
b. Current health (go to 4) 
c. Same (stop) 
 
 
4. If you were given the choice to live for 
10 years in your current state of health or 
to live for 6 years in perfect health, which 
would you prefer? 
a. Perfect health (go to 4a) 
b. Current health (go to 5) 
c. Same (stop) 
 
4a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 5.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
 
5. If you were given the choice to live for 
10 years in your current state of health or 
to live for 7 years in perfect health, which 
would you prefer? 
a. Perfect health (go to 5a) 
b. Current health (go to 6) 
c. Same (stop) 
 
5a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 6.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
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6. If you were given the choice to live for 
10 years in your current state of health or 
to live for 8 years in perfect health, which 
would you prefer? 
a. Perfect health (go to 6a) 
b. Current health (go to 7) 
c. Same (stop) 
 
6a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 7.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
 
7. If you were given the choice to live for 
10 years in your current state of health or 
to live for 9 years in perfect health, which 
would you prefer? 
a. Perfect health (go to 7a) 
b. Current health (go to 8) 
c. Same (stop) 
 
7a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 8.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
 
8. If you were given the choice to live for 
10 years in your current state of health or 
to live for 10 years in perfect health, 
which would you prefer? 
a. Perfect health (go to 8a) 
b. Current health (stop) 
c. Same (stop) 
 
8a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 9.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
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Script ii 
4. If you were given the choice to live for 
10 years in your current state of health or 
to live for 4 years in perfect health, which 
would you prefer? 
a. Perfect health (go to 4a) 
b. Current health (go to 5) 
c. Same (stop) 
 
4a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 4.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
 
5. If you were given the choice to live for 
10 years in your current state of health or 
to live for 3 years in perfect health, which 
would you prefer? 
a. Perfect health (go to 5a) 
b. Current health (go to 6) 
c. Same (stop) 
 
5a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 3.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
 
6. If you were given the choice to live for 
10 years in your current state of health or 
to live for 2 years in perfect health, which 
would you prefer? 
a. Perfect health (go to 6a) 
b. Current health (go to 7) 
c. Same (stop) 
 
6a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 2.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
 
7. If you were given the choice to live for 7a. If you were given the choice to live for 
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10 years in your current state of health or 
to live for 1 year in perfect health, which 
would you prefer? 
a. Perfect health (go to 7a) 
b. Current health (go to 8) 
c. Same (stop) 
 
10 years in your current state of health or 
to live for 1.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
 
8. If you were given the choice to live for 
10 years in your current state of health or 
to die immediately (0 years perfect 
health), which would you prefer? 
a. Perfect health (go to 8a) 
b. Current health (stop) 
c. Same (stop) 
 
8a. If you were given the choice to live for 
10 years in your current state of health or 
to live for 0.5 years in perfect health, 
which would you prefer? 
a. Perfect health (stop) 
b. Current health (stop) 
c. Same (stop) 
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Script iiia 
3. If you were given the choice to live for 5 
years in perfect health followed by 5 years 
in your current state of health or to die 
immediately, which would you prefer? 
a. 5 perfect, 5 current (go script 
iiib) 
b. Die immediately (go to 4) 
c. Same (stop) 
 
4. If you were given the choice to live for 6 
years in perfect health followed by 4 years 
in your current state or to die 
immediately, which would you prefer? 
a. 6 perfect, 4 current (go to 4a) 
b. Immediate death (go to 5) 
c. Same (stop) 
4a. If you were given the choice to live for 
5.5 years in perfect health followed by 4.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 5.5 perfect, 4.5 current (stop) 
b. Die immediately (stop) 
c. Same (stop) 
5. If you were given the choice to live for 7 
years in perfect health followed by 3 years 
in your current state or to die 
immediately, which would you prefer? 
a. 7 perfect, 3 current (go to 5a) 
b. Die immediately (go to 6) 
c. Same (stop) 
5a. If you were given the choice to live for 
6.5 years in perfect health followed by 3.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 6.5 perfect, 3.5 current (stop) 
b. Die immediately (stop) 
c. Same (stop) 
6. If you were given the choice to live for 8 
years in perfect health followed by 2 years 
in your current state or to die 
6a. If you were given the choice to live for 
7.5 years in perfect health followed by 2.5 
years in your current state or to die 
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immediately, which would you prefer? 
a. 8 perfect, 2 current (go to 6a) 
b. Die immediately (go to 7) 
c. Same (stop) 
immediately, which would you prefer? 
a. 7.5 perfect, 2.5 current (stop) 
d. Die immediately (stop) 
e. Same (stop) 
7. If you were given the choice to live for 9 
years in perfect health followed by 1 years 
in your current state or to die 
immediately, which would you prefer? 
a. 9 perfect, 1 current (go to 7a) 
b. Die immediately (go to 8) 
c. Same (stop) 
7a. If you were given the choice to live for 
8.5 years in perfect health followed by 1.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 8.5 perfect, 1.5 current (stop) 
b. Die immediately (stop) 
c. Same (stop) 
8. If you were given the choice to live for 
10 years in perfect health or to die 
immediately, which would you prefer? 
a. 10 perfect health (go to 8a) 
b. Die immediately (stop) 
c. Same (stop) 
8a. If you were given the choice to live for 
9.5 years in perfect health followed by 0.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 9.5 perfect, 0.5 current (stop) 
b. Die immediately (stop) 
c. Same (stop) 
 
Script iiib 
4. If you were given the choice to live for 4 
years in perfect health followed by 6 years 
in your current state or to die 
immediately, which would you prefer? 
a. 4 perfect, 6 current (go to 4a) 
b. Die immediately (go to 5) 
4a. If you were given the choice to live for 
4.5 years in perfect health followed by 5.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 4.5 perfect, 5.5 current (stop) 
b. Die immediately (stop) 
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c. Same (stop) c. Same (stop) 
5. If you were given the choice to live for 3 
years in perfect health followed by 7 years 
in your current state or to die 
immediately, which would you prefer? 
a. 3 perfect, 7 current (go to 5a) 
b. Die immediately (go to 6) 
c. Same (stop) 
5a. If you were given the choice to live for 
3.5 years in perfect health followed by 6.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 3.5 perfect, 6.5 current (stop) 
b. Die immediately (stop) 
c. Same (stop) 
6. If you were given the choice to live for 2 
years in perfect health followed by 8 years 
in your current state or to die 
immediately, which would you prefer? 
a. 2 perfect, 8 current (go to 6a) 
b. Die immediately (go to 7) 
c. Same (stop) 
6a. If you were given the choice to live for 
2.5 years in perfect health followed by 7.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 2.5 perfect, 7.5 current (stop) 
b. Die immediately (stop) 
c. Same (stop) 
7. If you were given the choice to live for 1 
years in perfect health followed by 9 years 
in your current state or to die 
immediately, which would you prefer? 
a. 1 perfect, 9 current (go to 7a) 
b. Die immediately (go to 8) 
c. Same (stop) 
7a. If you were given the choice to live for 
1.5 years in perfect health followed by 8.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 1.5 perfect, 8.5 current (stop) 
b. Die immediately (stop) 
c. Same (stop) 
8. If you were given the choice to live for 
10 years in your current health state or to 
die immediately, which would you prefer? 
a. 10 current health (go to 8a) 
b. Die immediately (stop) 
8a. If you were given the choice to live for 
0.5 years in perfect health followed by 9.5 
years in your current state or to die 
immediately, which would you prefer? 
a. 0.5 perfect, 9.5 current (stop) 
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c. Same (stop) b. Die immediately (stop) 
c. Same (stop) 
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Chapter 4 
Online TTO developed with Accent Marketing and Research Ltd. 
Example screenshot: 
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Chapter 5 
DCE choices 
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Note: task 17 is additional dominant choice added to 16 run main effects design and 
excluded from analysis 
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Chapter 7 
Converting Visual function data to approximate visual field 
Method for extracting points seen on microperimeter to approximate a visual 
field: 
1. Extract raw points displayed to patient by microperimeter using x and y 
coordinates. 
2. Convert to distance from centre of vision [(x^2+y^2)^0.5] = d 
3. Censor points with coordinates that were displayed outside of plausible 
visual field (d>17) 
4. Define whether point was seen by the patient (TRUE) or not seen by the 
patient (FALSE) 
5. Calculate proportion of points seen by the patient within the plausible 
visual field [SEEN/(SEEN+NOT SEEN)] 
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Review of AMD economic models 
Chapter 2 
Data extraction from AMD economic models 
 Intervention Comparato
r 
Utilities Efficacy Reported ICER 
Hernande
z-Pastor 
et al. 
(2008)(62
) 
Ranibizumab PDT with 
verteporfin 
Brown et al. 
(2000) 
VA from 
ANCHOR 
€131,275/QALY 
(2 year time 
horizon) 
Patel et al. 
(2010)(11
2) 
Bevacizumab Ranibizuma
b 
Modified 
from Brown 
et al. (2000) 
VA from 
MARINA and 
ANCHOR 
$1,405/QALY 
(bevacizumab) 
and 
$12,177/QALY 
(ranibizumab) 
Raftery et 
al. 
(2007)(14
5) 
Ranibizumab Bevacizum
ab 
Brown et al. 
(2000) 
VA from 
MARINA and 
specified 
range 
N/A (efficacy and 
price ranges 
modelled) 
Smith et 
al. 
(2004)(14
6) 
PDT with 
verteporfin 
Placebo Brown et al. 
(2000) 
VA from TAP £76,000 (starting 
VA 20/40, 2 year 
time horizon) 
Bansback 
et al. 
(2007)(60
) 
PDT with 
verteporfin 
BSC Espallargue
s et al. 
(2005) 
CS from TAP £20,996 (10 year 
time horizon) 
 294 
 Intervention Comparato
r 
Utilities Efficacy Reported ICER 
Neubauer 
et al. 
(2010)(14
7) 
Ranibizumab PDT/BSC Brown et al. 
(2000) 
(Bansback 
for 
sensitivitya
nalysis) 
VA from 
MARINA and 
ANCHOR 
ranibizumab for 
occult, minimally 
classic CNV, and 
classic CNV were 
€22,320, 
€22,538, and 
€25,036, /QALY 
respectively, and 
€3294 for classic 
CNV compared 
with PDT 
Gower et 
al. 
(2010)(14
8) 
Pegaptanib or 
ranibizumab 
PDT with 
verteporfin 
Brown et al. 
(2000) 
Various Various 
Fletcher et 
al. 
(2008)(14
9) 
Ranibizumab BSC Sharma 
(2000) 
VA from 
MARINA 
$626,938 per 
QALY 
Brown et 
al. 
(2008)(15
0) 
Ranibizumab Sham (no 
treatment) 
Brown et al. 
(2000) 
MARINA $50 691/QALY 
Karnon et 
al. 
(2008)(15
1) 
AMD screening No 
screening 
Espallargue
s et al. 
(2005) 
Uniform 
distribution 
for rate of 
uptake (no 
£15,169 (Annual 
screening, £2 per 
screen) 
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 Intervention Comparato
r 
Utilities Efficacy Reported ICER 
data) 
Bojke et 
al. 
(2008)(15
2) 
AMD screening 
followed by 
PDT 
PDT, no 
screening 
(self 
referral) 
and no 
screening, 
no PDT 
Brown et al. 
(2000) 
VA from TAP N/A (EVPI) 
Earnshaw 
et al. 
(2007)(15
3) 
Pegaptanib PDT and 
standard 
care 
Brown et al. 
(2000) 
VA from 
VISION and 
TAP 
$49,052 vs PDT 
and $59,039 vs 
standard care 
Wolowacz 
et al. 
(2007)(15
4) 
Pegaptanib BSC Not 
reported 
VA PharmacoEcono
mics [1170-
7690] Wolowacz 
Year: 2007 
Volume: 25 Issue: 
10 Page: 863 -79 
Brown et 
al. 
(2005)(15
5) 
PDT with 
verteporfin 
 233 patients VA from TAP US$31,103/QALY 
Hopley et 
al. 
(2004)(15
6) 
PDT with 
verteporfin 
Placebo Brown et al. 
(2000) 
VA from TAP £31,607/QALY 
(6/12 starting 
VA) 
Hopley et Screening for No Sharma et VA from £22,722/QALY 
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 Intervention Comparato
r 
Utilities Efficacy Reported ICER 
al. 
(2004)(15
7) 
early AMD 
followed by 
high dose zinc 
treatment al. (2000) AREDS and 
Blue 
Mountains Eye 
Study 
Busbee et 
al. 
(2003)(15
8) 
Laser 
photocoagulati
on 
Placebo Brown et al. 
(2000) 
VA from MPS US$$23,176/QAL
Y 
Sharma et 
al. 
(2001)(15
9) 
PDT with 
verteporfin 
Placebo Brown et al. 
(2000) and 
physician 
panel for 
complicatio
ns 
VA from TAP US$86,721/QALY 
(US 3rd party 
payer 
perspective, 
20/40 starting 
VA) 
Hurley et 
al. 
(2008)(16
0)  
Ranibizumab No 
treatment 
Brown et al. 
(2000) 
VA from 
MARINA 
US$91,900/QALY 
Javitt 
(2008)(74
) 
Pegaptanib Usual care Brown et al. 
(2000) 
VA from 
VISION 
 
Hurley 
(2008)(16
1) 
Smoking 
cessation 
Smoking Brown et al. 
(2000) 
VA from 
MARINA 
US$$200/QALY 
 
